SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(MARK ONE)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2020
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number: 001-39292
Butterfly Network, Inc.
(Exact name of registrant as specified in its charter)
| | |
Delaware | | 84-4618156 |
(State or other jurisdiction of incorporation or organization) | | ( Identification No.) |
| | |
530 Old Whitfield Street Guilford, Connecticut | | 06437 |
(Address of principal executive offices) | | (Zip Code) |
(203) 689-5650
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| | | | |
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Class A common stock, $0.0001 Par Value Per Share | | BFLY | | The New York Stock Exchange |
Warrants to purchase one share of Class A common stock, | ||||
| BFLY WS | | The New York Stock Exchange |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | ||||
Large accelerated filer | ¨ | Accelerated filer | ¨ | | |
| | | | | |
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | ||
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒☐ No ☐
| | Page | ||
|---|---|---|---|---|
| | | | |
| | | 2 | |
| | | | |
| | 3 | ||
| | | | |
| | 3 | ||
| | | | |
| | Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020 (Unaudited) | | 3 |
| | | | |
| | | 4 | |
| | | | |
| | | 5 | |
| | | | |
| | | 6 | |
| | | | |
| | Notes to | | 7 |
| | | | |
| Management’s Discussion and Analysis of Financial Condition and Results of Operations | | 23 | |
| | | | |
| Quantitative and Qualitative Disclosures | | 33 | |
| | | | |
| | 34 | ||
| | | | |
| | 33 | ||
| | | | |
| | 35 | ||
| | | | |
| | 35 | ||
| | | | |
| | 35 | ||
| | | | |
| | 35 | ||
| | | | |
| | 36 | ||
| | | | |
| | 36 | ||
| | | | |
| | 36 | ||
| | | | |
| | | 21 | |
| | | | |
In this Quarterly Report on Form 10-Q, the terms “we,” “us,” “our,” the “Company” and “Butterfly” mean Butterfly Network, Inc. (formerly Longview Acquisition Corp.) and our subsidiaries. On February 12, 2021 (the “Closing Date”), Longview Acquisition Corp., a Delaware corporation (“Longview” and after the Business Combination described herein, the “Company”), consummated a business combination (the “Business Combination”) pursuant to the terms of the Business Combination Agreement, dated as of November 19, 2020 (the “Business Combination Agreement”), by and among Longview, Clay Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and Butterfly Network, Inc., a Delaware corporation (“Legacy Butterfly”). Immediately upon the consummation of the Business Combination and the other transactions contemplated by the Business Combination Agreement (collectively, the “Transactions”, and such completion, the “Closing”), Merger Sub merged with and into Legacy Butterfly, with Legacy Butterfly surviving the Business Combination as a wholly-owned subsidiary of Longview (the “Merger”). In connection with the Transactions, Longview changed its name to “Butterfly Network, Inc.” and Legacy Butterfly changed its name to “BFLY Operations, Inc.”
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that relate to future events or our future financial performance regarding, among other things, the plans, strategies and prospects, both business and financial, of the Company. These statements are based on the beliefs and assumptions of the Company’s management team. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, the Company cannot assure you that it will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates” or “intends” or similar expressions. The forward-looking statements are based on projections prepared by, and are the responsibility of, the Company’s management. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:
| ● | our rapid growth may not be sustainable and depends on our ability to attract and retain customers; |
| ● | our business could be harmed if we fail to manage our growth effectively; |
| ● | the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition and our ability to grow and manage growth profitably and retain our key employees; |
| ● | our projections are subject to risks, assumptions, estimates and uncertainties; |
| ● | our business is subject to a variety of U.S. and foreign laws, which are subject to change and could adversely affect our business; |
| ● | the success, cost and timing of our product development activities; |
| ● | the potential attributes and benefits of our products and services; |
| ● | our ability to obtain and maintain regulatory approval for our products, and any related restrictions and limitations of any approved product; |
| ● | our ability to identify, in-license or acquire additional technology; |
| ● | our ability to maintain our existing license, manufacturing and supply agreements; |
| ● | our ability to compete with other companies currently marketing or engaged in the development of ultrasound imaging devices, many of which have greater financial and marketing resources than us; |
| ● | the size and growth potential of the markets for our products and services, and the ability of each to serve those markets, either alone or in partnership with others; |
| ● | the pricing of our products and services and reimbursement for medical procedures conducted using our products and services; |
| ● | changes in applicable laws or regulations; |
| ● | our ability to remediate the material weakness in our internal controls over financial reporting; |
| ● | our estimates regarding expenses, revenue, capital requirements and needs for additional financing; |
| ● | our ability to raise financing in the future; |
| ● | our financial performance; |
| ● | failure to protect or enforce our intellectual property rights could harm our business, results of operations and financial condition; |
| ● | the ability to maintain the listing of our Class A common stock on the NYSE; |
| ● | economic downturns and political and market conditions beyond our control could adversely affect our business, financial condition and results of operations; and |
| ● | the impact of the COVID-19 pandemic on our business. |
These and other risks and uncertainties are described in greater detail under the caption “Risk Factors” in Item 1A of Part I of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, in Item 1A of Part II of this quarterly report, and in other filings that we make with the Securities and Exchange Commission, or SEC. The risks described under the heading “Risk Factors” are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can the Company assess the impact of all such risk factors on its business or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. The Company undertakes no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
2
PART I -— FINANCIAL INFORMATION
| ASSETS | ||||
| Current assets: | ||||
| Cash | $ | 759,102 | ||
| Prepaid expenses and other current assets | 240,602 | |||
| Total Current Assets | 999,704 | |||
| Investments held in Trust Account | 414,222,151 | |||
| TOTAL ASSETS | $ | 415,221,855 | ||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||
| Current liabilities | ||||
| Accrued expenses | $ | 280,690 | ||
| Income taxes payable | 29,152 | |||
| Total Current Liabilities | 309,842 | |||
| Deferred underwriting fee payable | 14,490,000 | |||
| TOTAL LIABILITIES | 14,799,842 | |||
| Commitments and Contingencies | ||||
| Class A common stock, $0.0001 par value, subject to possible redemption, 39,542,201 shares at $10.00 per share | 395,422,010 | |||
| Stockholders’ Equity | ||||
| Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding | — | |||
| Class A common stock, $0.0001 par value; 200,000,000 shares authorized; 1,857,799 issued or outstanding (excluding 39,542,201 shares subject to possible redemption) | 186 | |||
| Class B common stock, $0.0001 par value; 20,000,000 shares authorized; 10,350,000 shares issued and outstanding | 1,035 | |||
| Additional paid-in capital | 5,389,917 | |||
| Accumulated deficit | (391,135 | ) | ||
| Total Stockholders’ Equity | 5,000,003 | |||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 415,221,855 | ||
(In thousands, except share and per share amounts)
(Unaudited)
| | | | | | | |
|
| March 31, |
| December 31, | | ||
|
| 2021 |
| 2020 |
| ||
Assets | |
| | |
| | |
Current assets: | |
| | |
| | |
Cash and cash equivalents | | $ | 18,850 | | $ | 60,206 | |
Marketable securities | | | 526,441 | | | — | |
Accounts receivable, net | |
| 5,237 | |
| 5,752 | |
Inventories | |
| 36,128 | |
| 25,805 | |
Current portion of vendor advances | | | 9,170 | | | 2,571 | |
Prepaid expenses and other current assets | |
| 9,358 | |
| 2,998 | |
Total current assets | | $ | 605,184 | | $ | 97,332 | |
Property and equipment, net | | | 7,254 | | | 6,870 | |
Non-current portion of vendor advances | |
| 32,535 | |
| 37,390 | |
Other non-current assets | |
| 2,505 | |
| 5,599 | |
Total assets | | $ | 647,478 | | $ | 147,191 | |
Liabilities, convertible preferred stock and stockholders’ equity (deficit) | |
| | | | | |
Current liabilities: | |
|
| |
|
| |
Accounts payable | | $ | 5,268 | | $ | 16,400 | |
Deferred revenue, current | |
| 9,548 | |
| 8,443 | |
Accrued purchase commitments, current | |
| 22,890 | |
| 22,890 | |
Accrued expenses and other current liabilities | | | 14,666 | | | 21,962 | |
Total current liabilities | | $ | 52,372 | | $ | 69,695 | |
Deferred revenue, non-current | | | 4,014 | | | 2,790 | |
Convertible debt | | | — | | | 49,528 | |
Loan payable | | | — | | | 4,366 | |
Warrant liabilities | | | 133,214 | | | — | |
Accrued purchase commitments, non-current | | | 19,660 | | | 19,660 | |
Other non-current liabilities | | | 2,055 | | | 2,146 | |
Total liabilities | | $ | 211,315 | | $ | 148,185 | |
Commitments and contingencies (Note 16) | | | | | | | |
Convertible preferred stock: | | | | | | | |
Convertible preferred stock (Series A, B, C and D) $.0001 par value with an aggregate liquidation preference of $0 and $383,829 at March 31, 2021 and December 31, 2020, respectively; 0 and 107,197,118 shares authorized, issued and outstanding at March 31, 2021 and December 31, 2020, respectively | | | — | | | 360,937 | |
Stockholders’ equity (deficit): | | | | | | | |
Class A common stock $.0001 par value; 600,000,000 and 116,289,600 shares authorized at March 31, 2021 and December 31, 2020, respectively; 164,862,470 and 6,593,291 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively | | | 16 | | | 1 | |
Class B common stock $.0001 par value; 27,000,000 and 26,946,089 shares authorized at March 31, 2021 and December 31, 2020, respectively; 26,426,939 and 0 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively | | | 3 | | | — | |
Additional paid-in capital | | | 831,640 | | | 32,874 | |
Accumulated deficit | | | (395,496) | | | (394,806) | |
Total stockholders’ equity (deficit) | | $ | 436,163 | | $ | (361,931) | |
Total liabilities, convertible preferred stock and stockholders’ equity (deficit) | | $ | 647,478 | | $ | 147,191 | |
The accompanying notes are an integral part of the unauditedthese condensed consolidated financial statements.
3
Three Months Ended September 30, 2020 | For the Period from February 4, 2020 (Inception) Through September 30, 2020 | |||||||
| Formation and operating costs | $ | 462,905 | $ | 584,134 | ||||
| Loss from operations | (462,905 | ) | (584,134 | ) | ||||
| Other income: | ||||||||
| Interest earned on marketable securities held in Trust Account | 165,021 | 222,151 | ||||||
| Income (loss) before provision for income taxes | (297,884 | ) | (361,983 | ) | ||||
| Provision for income taxes | (29,152 | ) | (29,152 | ) | ||||
| Net loss | $ | (327,036 | ) | $ | (391,135 | ) | ||
| Weighted average shares outstanding of Class A redeemable common stock | 41,400,000 | 40,617,323 | ||||||
| Basic and diluted income per share, Class A | $ | 0.00 | $ | 0.00 | ||||
| Weighted average shares outstanding of Class B non-redeemable common stock (1) | 10,350,000 | 10,350,000 | ||||||
| Basic and diluted net loss per share, Class B | $ | (0.03 | ) | $ | (0.04 | ) | ||
(In thousands, except shares and per share amounts)
(Unaudited)
| | | | | | | |
| | Three months ended March 31, | | ||||
|
| 2021 |
| 2020 | | ||
Revenue: | | |
| | |
| |
Product | | $ | 9,595 | | $ | 7,209 | |
Subscription | |
| 2,848 | |
| 1,461 | |
Total revenue | | $ | 12,443 | | $ | 8,670 | |
Cost of revenue: | |
|
| |
|
| |
Product | | | 5,648 | | | 9,262 | |
Subscription | |
| 379 | |
| 244 | |
Total cost of revenue | | $ | 6,027 | | $ | 9,506 | |
Gross profit | | $ | 6,416 | | $ | (836) | |
Operating expenses: | | | | | | | |
Research and development | | $ | 15,716 | | $ | 12,516 | |
Sales and marketing | |
| 9,808 | |
| 5,915 | |
General and administrative | |
| 34,640 | |
| 5,242 | |
Total operating expenses | |
| 60,164 | |
| 23,673 | |
Loss from operations | | $ | (53,748) | | $ | (24,509) | |
Interest income | | $ | 239 | | $ | 199 | |
Interest expense | |
| (638) | |
| (5) | |
Change in fair value of warrant liabilities | | | 54,112 | | | — | |
Other income (expense), net | |
| (631) | |
| (29) | |
Loss before provision for income taxes | | $ | (666) | | $ | (24,344) | |
Provision for income taxes | |
| 24 | |
| 10 | |
Net loss and comprehensive loss | | $ | (690) | | $ | (24,354) | |
Net loss per common share attributable to Class A and B common stockholders, basic and diluted | | | (0.01) | | | (4.07) | |
Weighted-average shares used to compute net loss per share attributable to Class A and B common stockholders, basic and diluted | | | 105,916,706 | | | 5,979,232 | |
The accompanying notes are an integral part of the unauditedthese condensed consolidated financial statements.
4
BUTTERFLY NETWORK, INC.
CONDENSED STATEMENTCONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY
Class A Common Stock | Class B Common Stock | Additional Paid-in | Accumulated | Total Stockholders’ | ||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||||||||
| Balance – February 4, 2020 | — | $ | — | — | $ | — | $ | — | $ | — | $ | — | ||||||||||||||||
| Issuance of Class B common stock to Sponsor (1)(2) | — | — | 10,350,000 | 1,035 | 23,965 | — | 25,000 | |||||||||||||||||||||
| Net loss | — | — | — | — | — | (1,000 | ) | (1,000 | ) | |||||||||||||||||||
| Balance – March 31, 2020 | — | — | 10,350,000 | 1,035 | 23,965 | (1,000 | ) | 24,000 | ||||||||||||||||||||
| Sale of 41,400,000 Units, net of underwriting discounts | 41,400,000 | 4,140 | — | — | 390,504,008 | — | 390,508,148 | |||||||||||||||||||||
| Sale of 6,853,333 Private Placement Warrants | — | — | — | — | 10,280,000 | — | 10,280,000 | |||||||||||||||||||||
| Common stock subject to possible redemption | (39,574,904 | ) | (3,957 | ) | — | — | (395,745,083 | ) | — | (395,749,040 | ) | |||||||||||||||||
| Net loss | — | — | — | — | — | (63,099 | ) | (63,099 | ) | |||||||||||||||||||
| Balance – June 30, 2020 | 1,825,096 | $ | 183 | 10,350,000 | $ | 1,035 | $ | 5,062,890 | $ | (64,099 | ) | $ | 5,000,009 | |||||||||||||||
| Change in value of common stock subject to possible redemption | 32,703 | 3 | — | — | 327,027 | — | 327,030 | |||||||||||||||||||||
| Net loss | — | — | — | — | — | (327,036 | ) | (327,036 | ) | |||||||||||||||||||
| Balance – September 30, 2020 | 1,857,799 | $ | 186 | 10,350,000 | $ | 1,035 | $ | 5,389,917 | $ | (391,135 | ) | $ | 5,000,003 | |||||||||||||||
(In thousands, except share amounts)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | |
Three months ended March 31, 2020 | |||||||||||||||||||||||||
|
| |
|
| |
|
| |
|
| |
| |
|
| |
|
| |
|
| |
|
| |
| | Convertible | | | Class A | | Class B | | | | | | | | | | |||||||||
| | Preferred | | | Common | | Common | | Additional | | | | | Total | |||||||||||
| | Stock | | | Stock | | Stock | | Paid-In | | Accumulated | | Stockholders’ | ||||||||||||
| | Shares | | Amount | | | Shares | | Amount | | Shares | | Amount | | Capital | | Deficit | | Equity (Deficit) | ||||||
December 31, 2019 | | 107,197,118 | | $ | 360,937 | | | 5,939,950 | | $ | 1 | | — | | $ | — | | $ | 19,782 | | $ | (232,061) | | $ | (212,278) |
Net loss | | — | | | — | | | — | | | — | | — | | | — | | | — | | | (24,354) | | | (24,354) |
Common stock issued upon exercise of stock options | | — | | | — | | | 73,515 | | | — | | — | | | — | | | 154 | | | — | | | 154 |
Stock-based compensation expense | | — | | | — | | | — | | | — | | — | | | — | | | 2,697 | | | — | | | 2,697 |
March 31, 2020 | | 107,197,118 | | $ | 360,937 | | | 6,013,465 | | $ | 1 | | — | | $ | — | | $ | 22,633 | | $ | (256,415) | | $ | (233,782) |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
Three months ended March 31, 2021 | |||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | Convertible | | | Class A | | Class B | | | | | | | | | | |||||||||
| | Preferred | | | Common | | Common | | Additional | | | | | Total | |||||||||||
| | Stock | | | Stock | | Stock | | Paid-In | | Accumulated | | Stockholders’ | ||||||||||||
| | Shares | | Amount | | | Shares | | Amount | | Shares | | Amount | | Capital | | Deficit | | Equity (Deficit) | ||||||
December 31, 2020 | | 107,197,118 | | $ | 360,937 | | | 6,593,291 | | $ | 1 | | — | | $ | — | | $ | 32,874 | | $ | (394,806) | | $ | (361,931) |
Net loss | | — | | | — | | | — | | | — | | — | | | — | | | — | | | (690) | | | (690) |
Common stock issued upon exercise of stock options | | — | | | — | | | 3,155,050 | | | — | | — | | | — | | | 6,313 | | | — | | | 6,313 |
Conversion of convertible preferred stock | | (107,197,118) | | | (360,937) | | | 80,770,178 | | | 8 | | 26,426,939 | | | 3 | | | 360,926 | | | — | | | 360,937 |
Conversion of convertible debt | | — | | | — | | | 5,115,140 | | | 1 | | — | | | — | | | 49,916 | | | — | | | 49,917 |
Net equity infusion from the Business Combination | | — | | | — | | | 69,228,811 | | | 6 | | — | | | — | | | 361,281 | | | — | | | 361,287 |
Stock-based compensation expense | | — | | | — | | | — | | | — | | — | | | — | | | 20,330 | | | — | | | 20,330 |
March 31, 2021 | | — | | $ | — | | | 164,862,470 | | $ | 16 | | 26,426,939 | | $ | 3 | | $ | 831,640 | | $ | (395,496) | | $ | 436,163 |
The accompanying notes are an integral part of the unauditedthese condensed consolidated financial statements.
5
| Cash Flows from Operating Activities: | ||||
| Net loss | $ | (391,135 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Interest earned on marketable securities held in Trust Account | (222,151 | ) | ||
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses | (240,602 | ) | ||
| Accrued expenses | 280,690 | |||
| Income taxes payable | 29,152 | |||
| Net cash used in operating activities | (544,046 | ) | ||
| Cash Flows from Investing Activities: | ||||
| Investment of cash into Trust Account | (414,000,000 | ) | ||
| Net cash used in investing activities | (414,000,000 | ) | ||
| Cash Flows from Financing Activities | ||||
| Proceeds from issuance of Class B common stock to Sponsor | 25,000 | |||
| Proceeds from sale of Units, net of underwriting discounts paid | 405,720,000 | |||
| Proceeds from sale of Private Placement Warrants | 10,280,000 | |||
| Proceeds from promissory note – related party | 191,000 | |||
| Repayment from promissory note – related party | (191,000 | ) | ||
| Payment of offering costs | (721,852 | ) | ||
| Net cash provided by financing activities | 415,303,148 | |||
| Net Change in Cash | 759,102 | |||
| Cash – Beginning of period | — | |||
| Cash – End of period | $ | 759,102 | ||
| Supplemental Disclosure of Non-Cash Activities: | ||||
| Initial classification of common stock subject to possible redemption | $ | 395,812,140 | ||
| Change in value of common stock subject to possible redemption | $ | (390,130 | ) | |
| Deferred underwriting fee payable | $ | 14,490,000 | ||
(In thousands)
(Unaudited)
| | | | | | |
| | Three months ended March 31, | ||||
| | 2021 | | 2020 | ||
Cash flows from operating activities: | | | | | | |
Net loss |
| $ | (690) |
| $ | (24,354) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | |
| |
Depreciation and amortization | |
| 458 | |
| 285 |
Non-cash interest expense on convertible debt | | | 389 | | | 0 |
Stock-based compensation expense | | | 20,298 | | | 2,683 |
Change in fair value of warrant liabilities | | | (54,112) | | | 0 |
Other | | | 397 | | | 244 |
Changes in operating assets and liabilities: | |
| | | | |
Accounts receivable | | | 585 | | | (229) |
Inventories | |
| (10,324) | |
| 528 |
Prepaid expenses and other assets | | | (6,114) | | | (1,495) |
Vendor advances | | | (1,744) | | | 1,302 |
Accounts payable | | | (11,000) | | | 1,487 |
Deferred revenue | | | 2,329 | | | 1,407 |
Accrued expenses and other liabilities | | | (3,899) | | | (1,528) |
Net cash used in operating activities | | $ | (63,427) | | $ | (19,670) |
| | | | | | |
Cash flows from investing activities: | |
|
| |
|
|
Purchases of marketable securities | | | (691,908) | | | 0 |
Sales of marketable securities | | | 165,000 | | | 0 |
Purchases of property and equipment | |
| (1,289) | |
| (480) |
Net cash used in investing activities | | $ | (528,197) | | $ | (480) |
| |
| | |
| |
Cash flows from financing activities: | |
| | |
| |
Proceeds from exercise of stock options | |
| 6,283 | |
| 154 |
Net proceeds from equity infusion from the Business Combination | | | 548,403 | | | 0 |
Payment of loan payable | | | (4,366) | | | 0 |
Payments of debt issuance costs | | | (52) | | | 0 |
Net cash provided by financing activities | | $ | 550,268 | | $ | 154 |
Net (decrease) increase in cash and cash equivalents | | $ | (41,356) | | $ | (19,996) |
Cash and cash equivalents, beginning of period | | | 60,206 | | | 90,002 |
Cash and cash equivalents, end of period | | $ | 18,850 | | $ | 70,006 |
The accompanying notes are an integral part of the unauditedthese condensed consolidated financial statements.
6
Note 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS
Butterfly Network, Inc., formerly known as Longview Acquisition Corp. (the “Company” or “Butterfly”) was incorporated in Delaware on February 4, 2020. The Company was formed forCompany’s legal name became Butterfly Network, Inc. following the purposeclosing of entering into a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similarthe business combination with one or more businesses (thediscussed in Note 3 “Business Combination”).
The Company is an early stageinnovative digital health business whose mission is to democratize healthcare by making medical imaging accessible to everyone around the world. Butterfly’s solution uses a unique combination of software and emerging growth companyhardware technology to address the needs of point-of-care imaging. The hardware platform works alongside cloud-based software to provide image interpretation, content storage and as such, the Company is subjectacquisition assistance to all of the risks associated with early stage and emerging growth companies.
The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate non-operating incomeoperates wholly-owned subsidiaries in the form of interest income from the proceeds derived from the Initial Public Offering.
Although the Company has net tangible assets ofincurred recurring losses in each year since inception, the Company expects its cash and cash equivalents and marketable securities will be sufficient to fund operations for at least $5,000,001 either prior to or upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by applicable law or stock exchange rules and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by applicable law or stock exchange rules, or the Company decides to obtain stockholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 5), and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination and not to convert any shares in connection with a stockholder vote to approve a Business Combination or sell any shares to the Company in a tender offer in connection with a Business Combination. Additionally, each public stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the Initial transaction or do not vote at all.
Note 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements include the accounts of Butterfly Network, Inc. and its wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) forand pursuant to the accounting disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Certain information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnotenote disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to thesuch rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unauditedregulations. Therefore, these condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.
The condensed consolidated balance sheet as of December 31, 2020, included herein, was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including certain notes required by U.S. GAAP, required on an annual reporting basis. Certain prior period amounts have been reclassified to conform to the current period presentation.
In the opinion of management, the accompanying condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods. The results for the three months ended September 30, 2020 and for the period from February 4, 2020 (inception) through September 30, 2020March 31, 2021 are not necessarily indicative of the results to be expected for any subsequent quarter, the periodyear ending December 31, 2021, or any other period.
Except as described elsewhere in this Note 2 including under the heading “Recently Adopted Accounting Pronouncements” and Note 3 “Business Combination”, there have been no material changes to the Company’s significant accounting policies as described in the audited consolidated financial statements as of December 31, 2020 or for any future interim periods.
COVID-19 Outbreak
The Company is an “emerging growth company,” as defined in Section 2(a)outbreak of the Securities Act, as modifiednovel coronavirus (“COVID-19”), which was declared a pandemic by the Jumpstart Our Business Startups ActWorld Health Organization on March 11, 2020 and declared a National Emergency by the President of 2012 (the “JOBS Act”),the United States on March 13, 2020, has led to adverse impacts on the U.S. and it may take advantageglobal economies and created uncertainty regarding potential impacts on
7
the Company’s operating results, financial condition and cash flows. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition will depend on future developments that are applicablehighly uncertain, including those that result from new information that may emerge concerning COVID-19, the actions taken to other public companies that are not emerging growth companies including, but not limited to, not being required to comply withcontain or treat COVID-19 and the independent registered public accounting firm attestation requirementseconomic impacts of Section 404COVID-19.
The estimates of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation inimpact on the Company’s business may change based on new information that may emerge concerning COVID-19, the actions to contain it or treat its periodic reportsimpact and proxy statements,the economic impact on local, regional, national and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrationsconcentration of credit risk consist principally of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000.and cash equivalents, marketable securities and accounts receivable. At September 30, 2020, the Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
As of March 31, 2021 and December 31, 2020, 0 customer accounts for more than 10% of the Company’s accounts receivable. For the three months ended March 31, 2021 and 2020, 0 customer accounts for more than 10% of the total revenues.
Segment Information
The Company’s Chief Operating Decision Maker, its Chief Executive Officer (“CEO”), reviews the financial information presented on a consolidated basis for purposes of allocating resources and evaluating its financial performance. Accordingly, the Company has determined that it operates in a single reportable segment. Substantially all of the Company’s long-lived assets are located in the United States. Since the Company operates in 1 operating segment, all required financial segment information can be found in the condensed consolidated financial statements.
Use of Estimates
The Company makes estimates and assumptions about future events that affect the amounts reported in its condensed consolidated financial statements and accompanying notes. Future events and their effects cannot be determined with certainty. On an ongoing basis, management evaluates these estimates, judgments and assumptions.
The Company bases its estimates on historical and anticipated results and trends and on various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates, and any recently issued, but not yet effective, accounting standards, if currently adopted, would have asuch differences may be material effect onto the Company’s condensed consolidated financial statements.
Investments in Marketable Securities
The Company’s investments in marketable securities are ownership interests in mutual funds. The equity securities are stated at fair value, as determined by quoted market prices. As the securities have readily determinable fair value, unrealized gains and losses are reported as other income/(loss), net on the condensed consolidated statements of operations and comprehensive loss. Subsequent gains or losses realized upon redemption or sale of these securities are also recorded as other income/(loss), net on the condensed consolidated statements of operations and comprehensive loss. The Company considers all of its investments in marketable securities as available for use in current operations and therefore classifies these securities within current assets on the condensed consolidated balance sheets. For the three months ended March
8
31, 2021, the Company recognized $0.3 million of unrealized losses that relate to equity securities still held as of March 31, 2021.
Warrant Liability
The Company’s outstanding warrants include publicly-traded warrants (the “Public Warrants”) which were issued as one-third of a warrant per unit issued during the Company’s initial public offering on May 26, 2020 (the “IPO”) and warrants sold in a private placement to Longview’s sponsor (the “Private Warrants”). The Company evaluated its warrants under ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, and concluded that they do not meet the criteria to be classified in stockholders’ equity. Since the Public Warrants and Private Warrants meet the definition of a derivative under ASC 815, the Company sold 36,000,000 Unitsrecorded these warrants as long-term liabilities on the balance sheet at fair value upon the Closing of the Business Combination, with subsequent changes in their respective fair values recognized in the condensed consolidated statements of operations and comprehensive loss at each reporting date.
Recent Accounting Pronouncements Adopted
In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that Is a Service Contract (Topic 350-40),which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). As a result, eligible implementation costs incurred in a cloud computing arrangement that is a service contract are capitalized as prepaid expenses and other current assets on the balance sheet, recognized on a straight-line basis over its life in the statement of operations and comprehensive loss in the same line item as the fees for the associated arrangement, and the related activity is generally classified as an operating activity in the statement of cash flows. The Company prospectively adopted such guidance on January 1, 2021 and there was no material effect of adoption on the condensed consolidated financial statements as of and for the three months ended March 31, 2021.
Recent Accounting Pronouncements Issued but Not Yet Adopted
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) which outlines a comprehensive lease accounting model and supersedes the prior lease guidance. The new guidance requires lessees to recognize almost all of their leases on the balance sheet by recording a lease liability and corresponding right-of-use assets. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. As per the latest ASU 2020-05 issued by the FASB, entities who have not yet issued or made available for issuance their financial statements as of June 3, 2020 can defer the new guidance for one year. For public entities, this guidance was effective for annual reporting periods beginning January 1, 2019, including interim periods within that annual reporting period. For other entities, this guidance is effective for the annual reporting period beginning January 1, 2022, and interim reporting periods within annual reporting periods beginning January 1, 2023. This will require application of the new accounting guidance at the beginning of the earliest comparative period presented in the year of adoption. The impact of the Company's adoption of Topic 842 to the underwriters. consolidated financial statements will be to recognize the operating lease commitments as operating lease liabilities and right-of-use assets upon adoption, which will result in an increase in the assets and liabilities recorded on the balance sheet. The Company is continuing its assessment, which may identify additional impacts Topic 842 will have on the consolidated financial statements and disclosures.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires an entity to utilize a new impairment model known as the current expected credit loss (“CECL”) model to estimate its lifetime “expected credit loss” and record an allowance that, when deducted from the amortized cost basis of the financial asset, presents the net amount expected to be collected on the financial asset. The CECL model is expected to result in more timely recognition of credit losses. ASU 2016-13 also requires new disclosures for financial assets measured at amortized cost, loans, and available-for-sale debt securities. For public entities, this guidance was effective for annual reporting periods beginning January 1, 2020, including interim periods within that annual reporting period. For other entities, this guidance is effective for the annual reporting period beginning January 1, 2023, including interim periods within that annual reporting period. The standard will apply as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is
9
adopted. The Company is in the process of evaluating the impact the adoption of this pronouncement will have on the Company’s consolidated financial statements and disclosures.
Note 3. Business Combination
On June 9, 2020,February 12, 2021 (the “Closing Date”), the Company sold an additional 4,000,000 Units soldconsummated the previously announced business combination (the “Business Combination”) pursuant to the underwritersterms of the Business Combination Agreement, dated as of November 19, 2020 (the “Business Combination Agreement”), by and among Longview, Clay Merger Sub, Inc., a Delaware corporation incorporated on November 12, 2020 (“Merger Sub”), and Butterfly Network, Inc., a Delaware corporation (“Legacy Butterfly”).
Immediately upon the underwriters’ electionconsummation of the Business Combination and the other transactions contemplated by the Business Combination Agreement (collectively, the “Transactions”, and such completion, the “Closing”), Merger Sub merged with and into Legacy Butterfly, with Legacy Butterfly surviving the Business Combination as a wholly-owned subsidiary of Longview (the “Merger”). In connection with the Transactions, Longview changed its name to partially exercise their over-allotment“Butterfly Network, Inc.” and Legacy Butterfly changed its name to “BFLY Operations, Inc.”
The Merger is accounted for as a reverse recapitalization in accordance with U.S. GAAP primarily due to the fact that Legacy Butterfly stockholders continue to control the Company post the closing of the Business Combination. Under this method of accounting, Longview is treated as the “acquired” company for accounting purposes and the Business Combination is treated as the equivalent of Legacy Butterfly issuing stock for the net assets of Longview, accompanied by a recapitalization. The net assets of Longview will be stated at historical cost, with no goodwill or other intangible assets recorded. Reported shares and earnings per share available to holders of the Company’s capital stock and equity awards prior to the Business Combination have been retroactively restated reflecting the exchange ratio established in the Business Combination Agreement (1:1.0383).
Pursuant to the Merger, at the Effective Time of the Merger (the “Effective Time”):
each share of Legacy Butterfly capital stock (other than the Legacy Butterfly Series A preferred stock) that was issued and outstanding immediately prior to the Effective Time was automatically canceled and converted into the right to receive 1.0383 shares of the Company’s Class A common stock, rounded down to the nearest whole number of shares;
each share of Legacy Butterfly Series A preferred stock that was issued and outstanding immediately prior to the Effective Time was automatically canceled and converted into the right to receive 1.0383 shares of the Company’s Class B common stock, rounded down to the nearest whole number of shares;
| ||
• | each option to purchase shares of Legacy Butterfly common stock, whether vested or unvested, that was outstanding and unexercised as of immediately prior to the Effective Time was assumed by the Company and became an option (vested or unvested, as applicable) to purchase a number of shares of the Company’s Class A common stock equal to the number of shares of Legacy Butterfly common stock subject to such option immediately prior to the Effective Time multiplied by 1.0383, rounded down to the nearest whole number of shares, at an exercise price per share equal to the exercise price per share of such option immediately prior to the Effective Time divided by 1.0383 and rounded up to the nearest whole cent; | |
• | each Legacy Butterfly restricted stock unit outstanding immediately prior to the Effective Time was assumed by the Company and became a restricted stock unit with respect to a number of shares of the Company’s Class A common stock, rounded to the nearest whole share, equal to the number of shares of Legacy Butterfly common stock subject to such Legacy Butterfly restricted stock unit immediately prior to the Effective Time multiplied by 1.0383; and |
10
the principal amount plus accrued but unpaid interest, if any, on the Legacy Butterfly convertible notes outstanding as of immediately prior to the Effective Time was automatically canceled and converted into the right to receive shares of the Company’s Class A common stock, with such shares of the Company’s Class A common stock calculated by dividing the outstanding principal plus accrued interest, if any, of each Legacy Butterfly convertible note by $10.00, rounded down to the nearest whole number of shares.
In addition, on February 12, 2021, Longview filed the Second Amended and Restated Certificate of Incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware, which became effective simultaneously with the Effective Time. As a consequence of filing the Restated Certificate, the Company adopted a dual class structure, comprised of the Company’s Class A common stock, which is entitled to 1 vote per share, and the Company’s Class B common stock, which is entitled to 20 votes per share. The Company’s Class B common stock is subject to a “sunset” provision if Jonathan M. Rothberg, Ph.D., the founder of Legacy Butterfly and Chairman of the Company (“Dr. Rothberg”), and other permitted holders of the Company’s Class B common stock collectively cease to beneficially own at least 20 percent (20%) of the number of shares of the Company’s Class B common stock (as such number of shares is equitably adjusted in respect of any reclassification, stock dividend, subdivision, combination or recapitalization of the Company’s Class B common stock) collectively held by Dr. Rothberg and permitted transferees of the Company’s Class B common stock as of the Effective Time.
In addition, concurrently with the execution of the Business Combination Agreement, on November 19, 2020, Longview entered into subscription agreements (the “Subscription Agreements”) with certain institutional investors (the “PIPE Investors”), pursuant to which the PIPE Investors purchased, immediately prior to the Closing, an aggregate of 17,500,000 shares of Longview Class A common stock at a purchase price of $10.00 per Unit. On June 26, 2020,share (the “PIPE Financing”).
The total number of shares of the Company’s Class A common stock outstanding immediately following the Closing was approximately 164,862,470, comprising:
59 | ||
• | 95,633,659 shares of the Company’s Class A common stock issued to Legacy Butterfly stockholders (other than certain holders of Legacy Butterfly Series A preferred stock) and holders of Legacy Butterfly convertible notes in the Merger; |
17,500,000 shares of the Company’s Class A common stock issued in connection with the underwriters’ electionClosing to exercise their remaining over-allotment option,the PIPE Investors pursuant to the PIPE Financing;
| ||
• | 10,350,000 shares of the Company’s Class A common stock issued to holders of shares of Longview Class B common stock outstanding at the Effective Time; and | |
• | 41,378,811 shares of the Company’s Class A common stock issued to holders of Longview Class A commons stock outstanding at the Effective Time. |
The total number of shares of the Company’s Class B common stock issued at the Closing was approximately 26,426,939. Immediately following the Closing, Dr. Rothberg held approximately 76.2% of the combined voting power of the Company. Accordingly, Dr. Rothberg and his permitted transferees control the Company soldand the Company is a controlled company within the meaning of the corporate governance standards of the New York Stock Exchange (the “NYSE”).
The most significant change in the post-combination Company’s reported financial position and results was an increase in cash of $589.5 million. The Company as the accounting acquirer incurred $11.4 million in transaction costs
11
relating to the Business Combination, which has been offset against the gross proceeds recorded in additional paid-in capital in the condensed consolidated statements of changes in convertible preferred stock and stockholders’ equity (deficit). The Company on the date of Closing used proceeds of the Transactions to pay off $30.9 million, representing all significant liabilities of the acquiree excluding the warrant liability. As of the date of the Business Combination, the Company recorded net liabilities of $186.5 million with a corresponding offset to additional paid-in capital. The net liabilities include warrant liabilities of $187.3 million and other insignificant assets and liabilities. The Company received proceeds of $0.6 million related to other transactions that occurred at the same time as the Business Combination.
Note 4. Revenue Recognition
Disaggregation of Revenue
The Company disaggregates revenue from contracts with customers by product type and by geographical market. The Company believes that these categories aggregate the payor types by nature, amount, timing and uncertainty of their revenue streams. The following table summarizes the Company’s disaggregated revenues (in thousands) for the three months ended March 31, 2021 and 2020:
| | | | | | | | | |
| | Pattern of | | Three months ended March 31, | | ||||
|
| Recognition |
| 2021 |
| 2020 | | ||
By Product Type: | |
| |
| | |
| | |
Devices and accessories |
| Point-in-time | | $ | 9,595 | | $ | 7,209 | |
Subscription services and other services |
| Over time | |
| 2,848 | |
| 1,461 | |
Total revenue | | | | $ | 12,443 | | $ | 8,670 | |
By Geographical Market: | | | |
|
| |
|
| |
United States | | | | $ | 8,896 | | $ | 6,352 | |
International | | | |
| 3,547 | |
| 2,318 | |
Total revenue | | | | $ | 12,443 | | $ | 8,670 | |
Contract Balances
Contract balances represent amounts presented in the consolidated balance sheets when either the Company has transferred goods or services to the customer, or the customer has paid consideration to the Company under the contract. These contract balances include trade accounts receivable and deferred revenue. Deferred revenue represents cash consideration received from customers for services that are transferred to the customer over the respective subscription period. The accounts receivable balances represent amounts billed to customers for goods and services where the Company has an unconditional right to payment of the amount billed.
The following table provides information about receivables and deferred revenue from contracts with customers (in thousands):
| | | | | | |
|
| March 31, |
| December 31, | ||
| | 2021 | | 2020 | ||
Accounts receivable, net | | $ | 5,237 | | $ | 5,752 |
Deferred revenue, current | |
| 9,548 | |
| 8,443 |
Deferred revenue, non-current | |
| 4,014 | |
| 2,790 |
The Company recognizes a receivable when it has an unconditional right to payment, and payment terms are typically 30 days for all product and service sales. The allowance for doubtful accounts was $0.4 million and $0.6 million as March 31, 2021 and December 31, 2020, respectively.
The amount of revenue recognized during the three months ended March 31, 2021 and 2020 that was included in the deferred revenue balance at the beginning of the period was $3.3 million and $0.9 million, respectively.
12
The Company incurs incremental costs of obtaining contracts and costs of fulfilling contracts with customers. The amount of costs capitalized during the three months ended March 31, 2021 and 2020 was not significant.
Transaction Price Allocated to Remaining Performance Obligations
On March 31, 2021, the Company had $17.7 million of remaining performance obligations. The Company expects to recognize 61% of its remaining performance obligations as revenue in the next twelve months, and an additional 1,400,000 Units39% thereafter.
Note 5. Fair Value of Financial Instruments
Fair value estimates of financial instruments are made at a specific point in time, based on relevant information about financial markets and specific financial instruments. As these estimates are subjective in nature, involving uncertainties and matters of significant judgment, they cannot be determined with precision. Changes in assumptions can significantly affect estimated fair value.
The Company measures fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The Company utilizes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:
| ● | Level 1 — Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. |
| ● | Level 2 — Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. |
| ● | Level 3 — Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company has no assets or liabilities valued with Level 3 inputs. |
The carrying value of $10.00cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximates their fair values due to the short-term or on demand nature of these instruments.
There were no transfers between fair value measurement levels during the periods ended March 31, 2021 and December 31, 2020.
The Company determined the fair value of its Public Warrants as Level 1 financial instruments, as they are traded in active markets. Because any transfer of Private Warrants from the initial holder of the Private Warrants would result in the Private Warrants having substantially the same terms as the Public Warrants, management determined that the fair value of each Private Warrant is the same as that of a Public Warrant. Accordingly, the Private Warrants are classified as Level 2 financial instruments.
13
The following table summarizes the Company’s assets and liabilities that are measured at fair value on a recurring basis, by level, within the fair value hierarchy (in thousands):
| | | | | | | | | | | | |
| | | | | Fair Value Measurement Level | |||||||
| | Total | | Level 1 | | Level 2 | | Level 3 | ||||
March 31, 2021: |
| |
|
| |
|
| |
|
| |
|
Marketable securities: |
| |
|
| | |
| |
|
| |
|
Mutual funds | | $ | 526,441 | | $ | 526,441 | | $ | — | | $ | — |
Total assets at fair value on a recurring basis | | $ | 526,441 | | $ | 526,441 | | $ | — | | $ | — |
| | | | | | | | | | | | |
Warrants: | | | | | | | | | | | | |
Public Warrants | | $ | 89,010 | | $ | 89,010 | | $ | — | | $ | — |
Private Warrants | | | 44,204 | | | — | | | 44,204 | | | — |
Total liabilities at fair value on a recurring basis | | $ | 133,214 | | $ | 89,010 | | $ | 44,204 | | $ | — |
The Company did not have any assets or liabilities similar to those above requiring fair value measurement at December 31, 2020.
Note 6. Inventories
A summary of inventories is as follows at March 31, 2021 and December 31, 2020 (in thousands):
| | | | | | |
|
| March 31, |
| December 31, | ||
|
| 2021 |
| 2020 | ||
Raw materials | | $ | 19,805 |
| | 7,688 |
Work-in-progress | |
| 1,058 |
| | 865 |
Finished goods | |
| 15,265 |
| | 17,252 |
Total inventories | | $ | 36,128 | | $ | 25,805 |
Work-in-progress represents inventory items in intermediate stages of production by third party manufacturers. For the three months ended March 31, 2021 and 2020, net realizable value inventory adjustments and excess and obsolete inventory charges were not significant and were recognized in product cost of revenues.
Note 7. Non-Current Assets
The Company’s property and equipment, net includes $3.9 million and $3.4 million of accumulated depreciation at March 31, 2021 and December 31, 2020, respectively.
Other non-current assets consist of the following at March 31, 2021 and December 31, 2020 (in thousands):
| | | | | | |
|
| March 31, |
| December 31, | ||
|
| 2021 |
| 2020 | ||
Security deposits | | $ | 1,883 | | $ | 1,888 |
Deferred offering costs | |
| — | |
| 3,711 |
Other long-term assets | | | 622 | | | — |
Total other non-current assets | | $ | 2,505 | | $ | 5,599 |
14
Note 8. Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consist of the following at March 31, 2021 and December 31, 2020 (in thousands):
| | | | | | |
|
| March 31, |
| December 31, | ||
|
| 2021 |
| 2020 | ||
Employee compensation | | $ | 4,651 | | $ | 5,968 |
Customer deposits | |
| 904 | |
| 1,177 |
Accrued warranty liability | |
| 418 | |
| 646 |
Non-income tax | |
| 3,605 | |
| 3,695 |
Professional fees | |
| 2,458 | |
| 5,432 |
Vendor settlements | | | — | | | 2,975 |
Other | |
| 2,630 | |
| 2,069 |
Total other current liabilities | | $ | 14,666 | | $ | 21,962 |
Warranty expense activity for the three months ended March 31, 2021 and 2020 is as follows (in thousands):
| | | | | | | |
| | Three months ended March 31, | | ||||
|
| 2021 |
| 2020 | | ||
Balance, beginning of period | | $ | 1,826 | | $ | 876 | |
Warranty provision charged to operations | |
| (392) | |
| 723 | |
Warranty claims | |
| (248) | |
| (500) | |
Balance, end of period | | $ | 1,186 | | $ | 1,099 | |
The Company classifies its accrued warranty liability based on the timing of expected warranty activity. The future costs of expected activity greater than one year is recorded within other non-current liabilities on the condensed consolidated balance sheet.
Note 9. Convertible Preferred Stock
The Company has issued 4 series of Convertible Preferred Stock, Series A through Series D. The following table summarizes the authorized, issued and outstanding Convertible Preferred Stock of the Company as of immediately prior to the Business Combination and December 31, 2020 (in thousands, except share and per Unit. Each Unit consistsshare information):
| | | | | | | | | | | | | | | | | | | |
|
| |
| Issuance |
| Shares |
| Total |
| | |
| | |
| Initial | |||
| | | | Price | | Authorized, | | Proceeds or | | | | | Net | | Liquidation | ||||
| | Year of | | per | | Issued and | | Exchange | | Issuance | | Carrying | | Price per | |||||
Class | | Issuance | | share | | Outstanding | | Value | | Costs | | Value | | share | |||||
Series A |
| 2012 | | $ | 0.04 |
| 26,946,090 | | $ | 1,038 | | $ | 11 | | $ | 1,027 | | $ | 0.77 |
Series B |
| 2014 | |
| 0.77 |
| 25,957,500 | |
| 20,000 | |
| 99 | |
| 19,901 | |
| 0.77 |
Series C |
| 2014 – 2015 | |
| 3.21 |
| 29,018,455 | |
| 93,067 | |
| 246 | |
| 92,821 | |
| 3.21 |
Series D |
| 2018 | |
| 9.89 |
| 25,275,073 | |
| 250,000 | |
| 2,812 | |
| 247,188 | |
| 9.89 |
| | | | | |
| 107,197,118 | | | | | | | | | | | | |
Prior to the completion of one sharethe Business Combination there were no significant changes to the terms of the Convertible Preferred Stock. Upon the Closing of the Business Combination, the Convertible Preferred stock converted into Class A and Class B common stock based on the Business Combination’s conversion ratio of 1.0383 of the Company’s shares for each Legacy Butterfly share. The Company recorded the conversion at the carrying value of the Convertible Preferred Stock at the time of Closing. There are 0 shares of Convertible Preferred Stock outstanding as of March 31, 2021.
Note 10. Equity Incentive Plans
The Company’s 2012 Employee, Director and one-thirdConsultant Equity Incentive Plan (the “2012 Plan”) was adopted by its Board of one warrant (“Public Warrant”Directors and stockholders in March 2012. The Butterfly Network, Inc. Amended and Restated 2020 Equity Incentive Plan (the “2020 Plan”). Each whole Public Warrant entitles was approved by the holderBoard of Directors in the fourth quarter of 2020 and by the
15
stockholders in the first quarter of 2021. The Company granted to purchase one sharemembers of commonthe Company’s board of directors 0.1 million restricted stock at a price of $11.50 per share, subject to adjustment (see Note 7).
In connection with the closing of the Initial Public Offering, the Sponsor purchased 6,133,333 Private Placement Warrants at a price of $1.50 per Private Placement Warrant, for an aggregate purchase price of $9,200,000. On June 9, 2020, in connection with the underwriters’ election to partially exercise their over-allotment option,Business Combination, the Company sold an additional 533,333 Private Placement Warrantsadjusted the equity awards as described in Note 3 “Business Combination.” The adjustments to the Sponsor, ataward did not result in incremental expense as the equitable adjustments were made pursuant to a pricepreexisting nondiscretionary antidilution provision in the 2012 Plan, and the fair-value, vesting conditions, and classification are the same immediately before and after the modification.
Stock option activity
On January 23, 2021, the former Chief Executive Officer and member of $1.50 per Private Placement Warrant, generating gross proceedsthe Board of $800,000. On June 26, 2020, in connection withDirectors resigned from his position as Chief Executive Officer. Pursuant to the underwriters’ election to exercise their remaining over-allotment option,separation agreement between the former Chief Executive Officer and the Company, sold an additional 186,667 Private Placement Warrantsthe former officer received equity-based compensation. The equity compensation includes the acceleration of vesting of the officer’s service based options. The acceleration of 1.6 million options was pursuant to the Sponsor, at a priceoriginal option award agreement. The Company recognized $2.6 million of $1.50 per Private Placement Warrant, generating gross proceedsexpense related to the acceleration of $280,000. Each Private Placement Warrant is exercisablethis option award during the three months ended March 31, 2021.
During the three months ended March 31, 2021 the Company granted option awards to purchase 1.6 million shares of the Company’s Class A common stock. Each award will vest based on continued service which is generally over 4 years. The grant date fair value of the award will be recognized as stock-based compensation expense over the requisite service period. The grant date fair value was determined using similar methods and assumptions as those previously disclosed by the Company.
Restricted stock unit activity
In January 2021, the Company granted 1 million restricted stock units to certain employees. In 2020, the Company granted 1.9 million restricted stock units to certain employees and consultants, including a grant of 1 million restricted stock units to the Chairman of the Board and significant shareholder of Butterfly. The awards are subject to certain service conditions and performance conditions. The service condition for these awards is satisfied by providing service to the Company based on the defined service period per the award agreement. The performance-based condition is satisfied upon the occurrence of a business combination event as defined in the award agreement. The achievement of the performance condition was deemed satisfied for the period ended March 31, 2021, as the completion of the Business Combination occurred. The fair value of restricted stock units was estimated on the date of grant based on the fair value of the Company’s Class A common stock. Using the accelerated attribution method, the Company recognized stock-based compensation expense of $14.4 million for the three months ended of March 31, 2021. For each award, the Company recognizes the expense over the requisite service period as defined in the award agreement. During the three months ended March 31, 2021the Company recognized the full grant date fair of the award for the Chairman of the Board and one other select consultant as service to the Company was no longer required. For the remaining awards service is still required to continue to vest per the award agreements.
Excluding the performance-based restricted stock units, during the three months ended March 31, 2021 the Company granted restricted stock unit awards to receive 0.5 million shares of the Company’s Class A common stock. Each award will vest based on continued service which is generally over 4 years. The grant date fair value of the award will be recognized as stock-based compensation expense over the requisite service period. The fair value of restricted stock units was estimated on the date of grant based on the fair value of the Company’s Class A common stock.
16
The Company’s total stock-based compensation expense for all stock option and restricted stock unit awards for the periods presented was as follows (in thousands):
| | | | | | | |
| | Three months ended March 31, | | ||||
|
| 2021 |
| 2020 | | ||
Cost of revenue – subscription | | $ | — | | $ | 5 | |
Research and development | |
| 1,391 | |
| 1,259 | |
Sales and marketing | |
| 1,674 | |
| 533 | |
General and administrative | |
| 17,233 | |
| 886 | |
Total stock-based compensation expense | | $ | 20,298 | | $ | 2,683 | |
Note 11. Net Loss Per Share
We compute net income per share of Class A and Class B common stock using the two-class method. Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of each class of common stock at an exercise price of $11.50the Company outstanding during the period. Diluted net loss per share subjectis computed by giving effect to adjustment (see Note 7). A portionall potential shares of common stock of the proceeds fromCompany, including those presented in the Private Placement Warrants were addedtable below, to the extent dilutive. Basic and diluted net proceeds fromloss per share was the Initial Public Offering to be held insame for each period presented as the Trust Account. Ifinclusion of all potential shares of common stock of the Company outstanding would have been anti-dilutive. Since the Company was in a net loss position for all periods presented, basic EPS calculation excludes preferred stock as it does not complete a Business Combination within the Combination Period, the proceeds from the saleparticipate in net losses of the Private Placement Warrants held inCompany.
As the Trust Account will be used to fundCompany uses the redemptiontwo-class method required for companies with multiple classes of the Public Shares (subjectcommon stock, the following table presents the calculation of basic and diluted net loss per share for each class the Company’s common stock (in thousands, except share and per share amounts):
| | | | | | | | | | |
Three months ended March 31, 2021 | | | | | | | | | | |
| | | | | | | | Total | | |
|
| Class A |
| Class B |
| Common Stock | | |||
Numerator: | | |
| | |
|
| |
| |
Allocation of undistributed earnings | | $ | (598) | | $ | (92) | | $ | (690) | |
Numerator for basic and dilutive EPS – loss available to common stockholders | | $ | (598) | | $ | (92) | | $ | (690) | |
Denominator: | |
|
| |
|
| |
|
| |
Weighted-average common shares outstanding | |
| 91,822,338 | |
| 14,094,368 | |
| 105,916,706 | |
Denominator for basic and dilutive EPS – weighted-average common stock | |
| 91,822,338 | |
| 14,094,368 | |
| 105,916,706 | |
Basic and dilutive loss per share | | $ | (0.01) | | $ | (0.01) | | $ | (0.01) | |
| | | | | | | | | | |
Three months ended March 31, 2020 | | | | | | | | | | |
| | | | | | | | Total | | |
|
| Class A |
| Class B |
| Common Stock | | |||
Numerator: | | |
| | |
|
| |
| |
Allocation of undistributed earnings | | $ | (24,354) | | $ | — | | $ | (24,354) | |
Numerator for basic and dilutive EPS – loss available to common stockholders | | $ | (24,354) | | $ | — | | $ | (24,354) | |
Denominator: | |
|
| |
|
| |
|
| |
Weighted-average common shares outstanding | |
| 5,979,232 | |
| — | |
| 5,979,232 | |
Denominator for basic and dilutive EPS – weighted-average common stock | |
| 5,979,232 | |
| — | |
| 5,979,232 | |
Basic and dilutive loss per share | | $ | (4.07) | | $ | — | | $ | (4.07) | |
For the periods presented above, the net income per share amounts are the same for Class A and Class B common stock because the holders of each class are entitled to the requirements of applicable law), and the Private Placement Warrants will expire worthless.equal per share dividends or distributions in liquidation in accordance
17
with the Certificate of Incorporation. The undistributed earnings for each year are allocated based on the contractual participation rights of the Class A and Class B common shares as if the earnings for the year had been distributed. As the liquidation and dividend rights are identical, the undistributed earnings are allocated on a proportionate basis. Anti-dilutive common equivalent shares were as follows:
| ||||||||||||||||||||||||||||||||||||||||||||||||
Note 12. Related Party Transactions
Prior to the Closing of the Business Combination, there were no significant changes in the nature of the Company’s related party transactions since December 31, 2020. Pursuant to a First Addendum dated November 19, 2020 to the Amended and Restated Technology Services Agreement dated November 11, 2020 by and between the Company, 4Catalyzer Corporation (“4Catalyzer”), and other participant companies controlled by Dr. Rothberg (the “ARTSA”), Butterfly terminated its participation under the ARTSA immediately prior to the Effective Time of the Business Combination.
A summary of related-party transactions and balances with 4Catalyzer are as follows (in thousands):
| | | | | | |
| | Three months ended | ||||
| | March 31, | ||||
|
| 2021 |
| 2020 | ||
Total incurred for operating expenses | | $ | 433 | | $ | 1,602 |
| | | | | | |
|
| March 31, | | December 31, | ||
| | 2021 |
| 2020 | ||
Due from related parties | | $ | — | | $ | 38 |
Due to related parties | |
| 50 | |
| 154 |
Note 13. Loan Payable
In FebruaryMay 2020, the Sponsor purchased 8,625,000Company received loan proceeds of $4.4 million under the Paycheck Protection Program (“PPP”). The Company used the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The Company accounted for the loan as debt. Following the Closing of the Business Combination discussed in Note 3 “Business Combination”, the Company repaid the loan in full in February 2021. The Company recognized an insignificant amount of interest expense in the condensed consolidated statement of operations and comprehensive loss related to the loan.
Note 14. Convertible Debt
In the year ended December 31, 2020, the Company issued convertible debt for total gross proceeds of $50.0 million.
Pursuant to the terms of the debt, at the Effective Time of the Merger discussed in Note 3 “Business Combination”, the convertible debt was automatically cancelled and converted into the right to receive shares (the “Founder Shares”) of the Company’s Class BA common stock for an aggregate price of $25,000. In April 2020,stock. The debt was converted with $49.9 million, the Sponsor transferred 25,000 Founder Shares to eachnet carrying value of the Company’s director nominees, fordebt as of the close of the Business Combination, in stockholders’ equity with a total amount of 75,000 Founder Shares transferred. On May 20, 2020, the Company effected a stock dividend of 1,725,000 shares with respectcorresponding decrease to the Class B common stock, resultingconvertible debt for the principal, accrued interest and unamortized debt issuance costs in the initial stockholders holdingcondensed consolidated statement of operations and comprehensive loss.
18
The Company recorded interest expense and amortization expense for the issuance costs of $0.4 million for the three months ended March 31, 2021.
Note 15. Warrants
Public Warrants
The Company issued Public Warrants and Private Warrants in connection with its IPO. As of March 31, 2021, there were an aggregate of 10,350,000 Founder Shares. All13,800,000 outstanding Public Warrants, which entitle the holder to acquire Class A common stock. Each whole warrant entitles the registered holder to purchase 1 share of Class A common stock at an exercise price of $11.50 per share, subject to adjustment as discussed below, beginning on May 26, 2021. The warrants will expire on February 12, 2026 or earlier upon redemption or liquidation.
Redemptions
At any time while the warrants are exercisable, Butterfly may redeem not less than all of the outstanding Public Warrants:
| ● | at a price of $0.01 per warrant; |
| ● | upon a minimum of 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; |
| ● | provided that the last reported sale price of the Class A common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like and for certain issuances of Class A common stock and equity-linked securities as described below) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date Butterfly sends the notice of redemption to the warrant holders; and |
| ● | provided that there is an effective registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants, and a current prospectus relating thereto, available through the 30-day redemption period or Butterfly has elected to require the exercise of the warrants on a “cashless basis” (as described below). |
If the foregoing conditions are satisfied and per-share amounts have been retroactively restatedthe Company issues a notice of redemption of the Public Warrants at $0.01 per warrant, each holder of Public Warrants will be entitled to reflectexercise his, her or its Public Warrants prior to the stock dividend. The Founder Shares will automatically convert intoscheduled redemption date.
If the Company calls the Public Warrants for redemption for $0.01 as described above, the Company’s Board of Directors may elect to require any holder that wishes to exercise his, her or its Public Warrant to do so on a “cashless basis.” If the Company’s Board of Directors makes such election, all holders of Public Warrants would pay the exercise price by surrendering their warrants for that number of shares of Class A common stock atequal to the timequotient obtained by dividing (x) the product of a Business Combination, on a one-for-one basis, subject to certain adjustments, as described in Note 7.
Commencing 90 days after the warrants become exercisable, Butterfly may redeem not less than all of the outstanding Public Warrants and Private Warrants:
| ● | at $0.10 per warrant; |
| ● | upon a minimum of 30 days’ prior written notice of redemption; |
| ● | provided that the last reported sale price of the Class A common stock equals or exceeds $10.00 per share (as adjusted per stock splits, stock dividends, reorganizations, reclassifications, recapitalizations and the like) on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders; |
19
| ● | provided that the Private Warrants are also concurrently exchanged at the same price (equal to a number of shares of Class A common stock) as the outstanding Public Warrants; and |
| ● | provided that there is an effective registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants and a current prospectus relating thereto available throughout the 30-day redemption period. |
If the foregoing conditions are satisfied and the Company issues a notice of redemption of the warrants at $0.10 per warrant, each warrant holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date on a cashless basis and receive that number of shares based on the redemption date and the “fair market value” of the Class A common stock, in accordance with a table set forth in the warrant agreement.
The Company evaluated the Public Warrants under ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, in conjunction with the SEC Division of Corporation Finance’s April 12, 2021 Public Statement, Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”), and concluded that they do not meet the criteria to be classified in stockholders’ equity. Specifically, the exercise of the warrants may be settled in cash upon the occurrence of a tender offer or exchange offer in which the maker of the tender offer or exchange offer, upon completion of the tender offer or exchange offer, beneficially owns more than 50% of the outstanding shares of the Company’s stockholders havingClass A common stock, even if it would not result in a change of control of the rightCompany. This provision would preclude the warrants from being classified in equity and thus the warrants should be classified as a liability.
Private Warrants
As of March 31, 2021, there were 6,853,333 Private Warrants outstanding. The Private Warrants are identical to exchange theirthe Public Warrants, except that so long as they are held by Longview Investors LLC (the “Sponsor”) or any of its permitted transferees, (i) the Private Warrants and the shares of Class A common stock issuable upon the exercise of the Private Warrants were not transferable, assignable or saleable until 30 days after the completion of the Business Combination, (ii) the Private Warrants will be exercisable for cash securities or on a cashless basis, at the holder’s option, and (iii) the Private Warrants are not subject to Butterfly’s redemption option at the price of $0.01 per warrant. The Private Warrants are subject to Butterfly’s redemption option at the price of $0.10 per warrant, provided that the other property.
The Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consum mation of a Business Combination, without interest, or, at the lender’s discretion, up to $2,000,000 of such Working Capital Loans may be convertible into warrants of the post Business Combination entity. The warrants would be identical toevaluated the Private Placement Warrants. ExceptWarrants under ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, in conjunction with the SEC Division of Corporation Finance’s April 12, 2021 Public Statement, Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”), and concluded that they do not meet the foregoing,criteria to be classified in stockholders’ equity. Specifically, the terms of the warrants provide for potential changes to the settlement amounts dependent upon the characteristics of the warrant holder, and, because the holder of a warrant is not an input into the pricing of a fixed-for-fixed option on equity shares, such Working Capital Loans, if any, have not been determinedprovision would preclude the warrant from being classified in equity and no written agreements exist with respect to such loans. As of September 30, 2020, no Working Capital Loans were outstanding.
The Company entered into an agreement whereby, commencing on May 26, 2020 throughrecognized a gain of $54.1 million due as a change in fair value of warrant liabilities in the earliercondensed consolidated statement of the Company’s consummation of a Business Combination or its liquidation, the Company will pay an affiliate of the Sponsor a total of $10,000 per monthoperations and comprehensive loss for office space, utilities, administrative and support services. For the three months ended September 30, 2020 and forMarch 31, 2021. There were no exercises or redemptions of the Public Warrants or Private Warrants during the period from February 4, 2020 (inception) through September 30, 2020, the Company incurred and paid $30,000 and $40,000, respectively in fees for these services.ended March 31. 2021.
20
Note 16. Commitments and Uncertainties
Commitments
Operating leases:
The Company leases office space under operating leases. Minimum rental payments under operating leases are recognized on a straight-line basis over the impactterm of the COVID-19 pandemiclease. Rent expense under the operating lease was $0.6 million and $0.5 million in the three months ended March 31, 2021 and 2020, respectively.
The following is a schedule of future minimum rental payments under non-cancelable operating leases with initial terms in excess of one year (in thousands):
| | | |
Years ending December 31: |
| |
|
Remainder of 2021 | | $ | 873 |
2022 | |
| 2,043 |
2023 | |
| 1,934 |
2024 | |
| 1,904 |
2025 | |
| 1,987 |
Thereafter | |
| 7,354 |
Total future minimum rental payments | | $ | 16,095 |
Purchase commitments:
The Company enters into inventory purchase commitments with third-party manufacturers in the ordinary course of business. These commitments are generally non-cancellable and are based on sales forecasts. These agreements range from one to five-year periods and may contain fixed or minimum annual commitments, subject to certain provisions that allow the Company to renegotiate the commitment. The aggregate amount of minimum inventory purchase commitments as of March 31, 2021 was $156.1 million.
During 2019, the Company entered into an agreement with a certain third party manufacturing vendor. In November 2020, the Company and the vendor amended the 2019 inventory supply arrangement. The amended agreement included provisions to increase the aggregate purchase commitments to $169.3 million and extend the time frame of the agreement to December 2022. The provisions of the agreement also allow the Company, once the defined cumulative purchase threshold per the agreement is reached, to pay for a portion of the subsequent inventory purchases using the vendor advance.
The Company applied the guidance in Topic 330, Inventory to assess the purchase commitment as of March 31, 2021 and 2020 and determined no update to amounts previously recorded was required. The Company considered a variety of factors and data points when determining the existence and scope of a loss for the minimum purchase commitment. The factors and data points included Company specific forecasts which are reliant on the Company’s limited sales history, agreement specific provisions, macroeconomic factors and market and industry trends. Determining the loss is subjective and requires significant management judgment and estimates. Future events may differ from those assumed in the Company’s assessment, and therefore the loss may change in the future.
As of March 31, 2021, the Company has concludeda prepaid advance of $36.4 million, net of write-downs and an accrual of $42.6 million related to the agreement. The portion of the balances that while it is reasonably possibleexpected to be utilized in the next 12 months is included in current assets and current liabilities in the accompanying condensed consolidated balance sheets.
Other commitments:
The Company sponsors a 401(k) defined contribution plan covering all eligible U.S. employees. Contributions to the 401(k) plan are discretionary. The Company did not make any matching contributions to the 401(k) plan for the periods ended March 31, 2020 and December 31, 2020.
21
Contingencies
The Company is involved in litigation and legal matters from time to time, which have arisen in the normal course of business. Although the ultimate results of these matters are not currently determinable, management does not expect that the virus couldthey will have a negativematerial effect on the Company’s financial position, resultscondensed consolidated balance sheet, statements of operations and comprehensive loss, or statements of cash flows.
On December 14, 2020, Nidhish Nair, a purported stockholder of Longview, filed a lawsuit in the Supreme Court of the State of New York, County of New York, captioned Nair v. Longview Acquisition Corp., against Longview and the members of its operations and/or search forboard directors (the “Nair Complaint”). On December 16, 2020, Eric Lau, a target company,purported stockholder of Longview, filed a lawsuit in the specific impact is not readily determinable asSupreme Court of the dateState of these financial statements. The financial statements do not include any adjustments that might result fromNew York, County of New York, captioned Lau v. Longview Acquisition Corp., against Longview, the outcomemembers of this uncertainty.
The Company enters into agreements that contain indemnification provisions with other parties in the ordinary course of business, including business partners, investors, contractors, customers, and the Company’s officers, or directors and any forward purchase shares issued as described in the prospectus.
22
| Held-To-Maturity | Amortized Cost | Gross Holding Gain | Level 1 Fair Value | ||||||||||
| September 30, 2020 | U.S. Treasury Securities (Mature on 11/27/2020) | $ | 414,221,183 | $ | 41,669 | $ | 414,262,851 | ||||||
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations” regardingOperations
The following discussion and analysis provides information which management believes is relevant to an assessment and understanding of our condensed consolidated results of operations and financial condition. The discussion should be read in conjunction with the Company’sunaudited condensed consolidated financial position, business strategystatements and notes thereto contained in this Quarterly Report on Form 10-Q and the plansconsolidated financial statements and objectives of managementnotes thereto for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and similar words and expressions are intendedthe year ended December 31, 2020 contained in Amendment No. 2 to identify such forward-looking statements. Suchthe Current Report on Form 8-K filed with the SEC on March 29, 2021. This discussion contains forward-looking statements relateand involves numerous risks and uncertainties, including, but not limited to, future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussedthose described in the forward-looking statements. For information identifying important factors that could cause actual“Risk Factors” sections of our Annual Report on Form 10-K for the year ended December 31, 2020, as amended, and of this Quarterly Report on Form 10-Q. Actual results tomay differ materially from those anticipatedcontained in any forward-looking statements. Unless the context otherwise requires, references to “we”, “us”, “our”, and “the Company” are intended to mean the business and operations of Butterfly Network, Inc. and its consolidated subsidiaries. The unaudited condensed consolidated financial statements for the three months ended March 31, 2021 and 2020, respectively, present the financial position and results of operations of Butterfly Network, Inc. and its wholly-owned subsidiaries.
Overview
We are an innovative digital health business whose mission is to democratize healthcare by making medical imaging accessible to everyone around the world. Powered by our proprietary Ultrasound-on-Chip™ technology, our solution uses a unique combination of software and hardware to address the needs of point-of-care imaging. Butterfly iQ, followed by our recently launched Butterfly iQ+, is our first product powered by Butterfly’s Ultrasound-on-Chip™, and is the only ultrasound transducer that can perform “whole-body imaging” in a single handheld probe using semiconductor technology. Our Ultrasound-on-Chip™ reduces the cost of manufacturing, while our software is intended to make the product easy to use and fully integrated with the clinical workflow, accessible on a user’s smartphone, tablet, and almost any hospital computer system connected to the Internet. Through our portable proprietary, handheld solution, protected by a robust intellectual property portfolio and empowered in part by its proprietary software and Artificial Intelligence (“AI”), Butterfly aims to enable earlier detection throughout the body and remote management of health conditions around the world.
The Butterfly iQ / iQ+ is currently cleared by the U.S. Food and Drug Administration (“FDA”) and has the CE mark for use by health care practitioners. It is commercially available in over 20 countries including, the United States, Canada, Australia, New Zealand and throughout greater Europe.
We are focused on driving the adoption of our handheld solution. We look to drive adoption by increasing the touchpoints with our customer, through new sales channels, as well as helping customers understand the power of point of care imaging in clinical decision making expanding its use cases and the settings where it is used. We also invest in upgrading our product. In October 2020, we launched the Butterfly iQ+, a second-generation version of our handheld probe which costs less to manufacture and features lower power consumption, faster frame rates and improved interoperability. Additionally, over the course of 2021, we launched multiple new software features that improve image acquisition and ease of use.
We are also focused on improving gross profits by focusing on operational efficiencies in our supply chain and expanding our customer relationships to incorporate higher margin products and services.
COVID-19
In December 2019, a novel coronavirus outbreak and related disease (known as COVID-19) was identified in Wuhan, China. In March 2020 the World Health Organization declared the outbreak of COVID-19 a pandemic. We are closely monitoring the impact of COVID-19 on all aspects of our business.
COVID-19 has disrupted, and we believe will continue to disrupt, our normal operations. There have been both positive and negative impacts, some quantifiable and others not quantifiable based on our limited historical data as an emerging growth company. Therefore, it is difficult for us to quantify the overall impact of the COVID-19 pandemic on our revenues.
23
In order to improve our liquidity during the COVID-19 pandemic, we obtained a loan under the Paycheck Protection Program (the “PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. We repaid the PPP loan in full in February 2021 from the proceeds of the Business Combination.
In terms of negative impacts, the pandemic has restricted the ability of our employees to travel, demonstrate our products to our potential customers and users, and perform other sales-generating activities. It has also impacted our ability to oversee the activities of our third-party manufacturers and suppliers, make shipments of materials, and pursue collaborations and other business transactions. COVID-19 has also caused the temporary closure of the facilities of certain of our suppliers, manufacturers and customers, and resulted in the forward-looking statements, please referimplementation of a temporary closure of our offices and the institution of a “work from home” policy. In addition, the COVID-19 pandemic and its economic impact have caused a financial strain on our customer base due to decreased funding and other revenue shortfalls. Reductions in budgets have resulted in delays in or decreases in the Risk Factors sectionsize of enterprise contracts. Given the lack of historical trends, we are unable to precisely quantify this impact.
Conversely, given those restrictions of access to our customers and “work from home” policy, one noticeable and quantifiable positive impact on our expenses was the reduction in our travel and related expenses, which for the quarter ended March 31, 2021 decreased by approximately $0.4 million, or 71%, year over year.
The COVID-19 pandemic also had a short-term early positive impact on our sales. We saw a spike in orders in March and April of 2020 because point-of-care ultrasound systems, like Butterfly iQ, have been utilized in the monitoring of acute symptoms of COVID-19 in patients through the use of lung ultrasound. Studies suggest that such systems may have a role to play in the assessment of lung involvement in COVID-19. The Butterfly iQ’s lung image quality, portability and ease of disinfection has made it particularly useful in assessing patients impacted by COVID-19. Given the lack of historical trends, we are unable to precisely quantify this impact.
The estimates of the Company’s final prospectus forimpact on our business may change based on new information that may emerge concerning COVID-19 and the actions to contain it or treat its Initial Public Offering filed withimpact and the U.S. Securitieseconomic impact on local, regional, national and Exchange Commission (the “SEC”). The Company’s securities filings can be accessed oninternational markets.
Despite these headwinds, we believe our business is well-positioned to benefit from the EDGAR sectiontrends, such as telemedicine, that are accelerating digital transformation of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whetherhealthcare industry as a result of new information, future eventsthe COVID-19 pandemic. For instance, we have developed a Teleguidance product that aligns with the larger industry trends to remote medicine. Additionally, we believe that our value proposition of improved patient care combined with a reduction in overall cost of service will further enhance adoption of the Butterfly solution.
We have not incurred any significant impairment losses in the carrying values of our assets as a result of the COVID-19 pandemic and we are not aware of any specific related event or otherwise.
Recent Developments
On February 12, 2021 we completed the business combination with Longview (the “Business Combination”) pursuant to the terms of the Business Combination Agreement, dated as of November 19, 2020 (the “Business Combination Agreement”), by and among Longview Acquisition Corp. (“Longview”), Clay Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and formedButterfly Network, Inc., a Delaware corporation (“Legacy Butterfly”). The Business Combination was approved by Longview's stockholders at its special meeting held on February 12, 2021. The transaction resulted in the Company being renamed to "Butterfly Network, Inc.," Legacy Butterfly being renamed “BFLY Operations, Inc.” and the Company’s Class A common stock and warrants to purchase Class A common stock commencing trading on the New York Stock Exchange ("NYSE") on February 16, 2021 under the symbol "BFLY" and “BFLY WS”, respectively. As a result of the Business Combination, we received gross proceeds of approximately $589 million.
Key Performance Metrics
We review the key performance measures discussed below, to evaluate business and measure performance, identify trends, formulate plans and make strategic decisions.
24
Units fulfilled
We define units fulfilled as the number of devices whereby control is transferred to a customer. We do not adjust this metric for returns as our volume of returns has historically been low. We view units fulfilled as a key indicator of the growth of our business. We believe that this metric is useful to investors because it presents our core growth and performance of our business period over period.
| | | | |
| | Three months ended March 31, | ||
| | 2021 | | 2020 |
Units fulfilled |
| 5,013 |
| 3,711 |
Units fulfilled increased by 1,302, or 35.1%, for the purposethree months ended March 31, 2021 compared to the three months ended March 31, 2020, primarily due to increased demand driven by additional investment in lead generation.
Subscription Mix
We define subscription mix as a percentage of effectingour total revenue recognized in a merger, capital stock exchange, asset acquisition, stock purchase, reorganizationreporting period that is subscription based, consisting primarily of our software as a service (“SaaS”) offering. We view subscription mix as a key indicator of the profitability of our business, and thus we believe that this metric is useful to investors. Because the costs and associated expenses to deliver our subscription offerings are lower as a percentage of sales than the costs of sales of our products, we believe a shift towards subscription will result in an improvement in profitability and margin expansion.
| | | | | |
| | Three months ended March 31, |
| ||
| | 2021 |
| 2020 |
|
Subscription mix |
| 22.9 | % | 16.9 | % |
Subscription mix increased by 6.0 percentage points, to 22.9% for the three months ended March 31, 2021 compared to the three months ended March 31, 2020, due to increased volume of device sales and increases in subscription renewals, as well as the timing of revenue recognition for our SaaS and other subscription contracts. Revenue from such contracts is deferred and recognized over the service period.
Non-GAAP Financial Measures
We present non-GAAP financial measures in order to assist readers of our condensed consolidated financial statements in understanding the core operating results that our management uses to evaluate the business and for financial planning purposes. Our non-GAAP financial measures, Adjusted Gross Profit and Adjusted EBITDA, provide an additional tool for investors to use in comparing our financial performance over multiple periods.
Adjusted Gross Profit and Adjusted EBITDA are key performance measures that our management uses to assess our operating performance. Adjusted Gross Profit and Adjusted EBITDA facilitate internal comparisons of our operating performance on a more consistent basis. We use these performance measures for business planning purposes and forecasting. We believe that Adjusted Gross Profit and Adjusted EBITDA enhance an investor’s understanding of our financial performance as they are useful in assessing our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.
Our Adjusted Gross Profit and Adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate these measures in the same manner. Adjusted Gross Profit and Adjusted EBITDA are not prepared in accordance with GAAP and should not be considered in isolation of, or similaras an alternative to, measures prepared in accordance with GAAP. When evaluating our performance, you should consider Adjusted Gross Profit and Adjusted EBITDA alongside other financial performance measures prepared in accordance with GAAP, including gross profit, operating loss, and net loss.
Adjusted Gross Profit
We calculate Adjusted Gross Profit as gross profit adjusted to exclude depreciation and amortization and non-recurring changes to our warranty liability. Our changes in the warranty liability are excluded from gross profit when they
25
are outside the normal course of operations for our business. The non-recurring warranty liability adjustments are for changes in our warranty policy resulting from a shift in product lines that impacted our estimate of future warranty costs.
The following table reconciles Adjusted Gross Profit to gross profit, the most directly comparable financial measure calculated and presented in accordance with GAAP.
| | | | | | | |
| | Three months ended March 31, | | ||||
| | 2021 | | 2020 | | ||
Revenue |
| $ | 12,443 |
| $ | 8,670 | |
Cost of revenue | |
| 6,027 | |
| 9,506 | |
Gross profit | | $ | 6,416 | | $ | (836) | |
Add: | |
|
| |
|
| |
Depreciation and amortization | |
| 89 | |
| 22 | |
Warranty liability policy change | | | (560) | | | — | |
Adjusted gross profit | | $ | 5,945 | | $ | (814) | |
Adjusted EBITDA
We calculate Adjusted EBITDA as net loss adjusted to exclude interest income, interest expense, other expense, net, provision for income taxes, depreciation and amortization, stock-based compensation, changes in the fair value of warrant liabilities and other non-recurring items. The other non-recurring items include costs related to our executive transition, discretionary transaction bonuses and other fees incurred with the close of the Business Combination and adjustments for the warranty liability policy changes. Our non-recurring discretionary bonuses are excluded from Adjusted EBITDA when they are outside the normal course of operations for our business and were given at the discretion of management due to the completion of the Business Combination. The non-recurring costs related to the executive transition include one-time severance and bonus payments and the recruiting expenses for our current CEO. The non-recurring warranty liability adjustments are for changes in our warranty policy resulting from a shift in product lines that impacted our estimate of future warranty costs.
The following table reconciles Adjusted EBITDA to net loss, the most directly comparable financial measure calculated and presented in accordance with one or more businesses. We intend to effectuate our initial Business Combination using cashGAAP.
| | | | | | | |
| | Three months ended March 31, | | ||||
(In thousands) | | 2021 | | 2020 | | ||
Net loss |
| $ | (690) |
| $ | (24,354) | |
Interest income |
| | (239) |
| | (199) | |
Interest expense |
| | 638 |
| | 5 | |
Change in fair value of warrant liabilities | | | (54,112) | | | — | |
Other expense, net |
| | 631 |
| | 29 | |
Provision for income taxes |
| | 24 |
| | 10 | |
Stock based compensation |
| | 20,298 |
| | 2,683 | |
Depreciation and amortization |
| | 458 |
| | 285 | |
CEO transition costs | | | 5,398 | | | — | |
Warranty liability policy change | | | (560) | | | — | |
Transaction bonus | | | 1,653 | | | — | |
Adjusted EBITDA |
| $ | (26,501) |
| $ | (21,541) | |
Description of Certain Components of Financial Data
Revenue
Revenue consists of revenue from the proceedssale of products such as medical devices, accessories, and related services, classified as subscription revenue on our Initial Public Offeringcondensed consolidated statements of operations and comprehensive loss, which are SaaS subscriptions and Support. SaaS subscriptions include licenses for teams and individuals as well as enterprise level subscriptions. For sales of products (which include the ultrasound devices and any ultrasound device accessories),
26
revenue is recognized at a point in time upon transfer of control to the customer. SaaS subscriptions and Support are generally related to stand-ready obligations and are recognized ratably over time.
Our product sales generate approximately 77.1% of our revenue, with our SaaS subscription revenue comprising the remaining 22.9%. As adoption of our devices increases through further market penetration and practitioners in the Butterfly network continue to use our devices, we expect our annual revenue mix to shift more toward subscriptions. The quarterly revenue mix may be impacted by the timing of device sales.
Cost of revenue
Cost of product revenue consists of product costs, including manufacturing costs, personnel costs and benefits, inbound freight, packaging, warranty replacement costs, payment processing fees and inventory obsolescence and write-offs. We expect our cost of product revenue to fluctuate over time due to the level of units fulfilled in any given period and decrease as a percentage of revenues over time as we focus on operational efficiencies in our supply chain.
Cost of subscription revenue consists of personnel costs, cloud hosting costs and payment processing fees. Because the costs and associated expenses to deliver our SaaS offerings are less than the costs and associated expenses of manufacturing and selling our device, we anticipate a natural improvement in profitability and margin expansion over time as our mix shifts increasingly towards subscriptions.
We plan to continue to invest additional resources into our products to expand and further develop our offerings. The level and timing of investment in these areas could affect our cost of revenue in the future.
Research and development (R&D)
Research and development expenses primarily consist of personnel costs and benefits, facilities-related expenses, depreciation expense, consulting and professional fees, fabrication services, software and other outsourcing expenses. Most of our research and development expenses are related to developing new products and services and improving existing products and services, which we define as not having reached the point of commercialization, and improving our products and services that have been commercialized. Consulting expenses are related to general development activities and clinical/regulatory research. Fabrication services include certain third-party engineering costs, product testing, and test boards. Research and development expenses are expensed as incurred. We expect to continue to make substantial investments in our product development, clinical and regulatory capabilities. Prospectively, we expect R&D spending as a percentage of revenues will increase in the near term and then fluctuate over time due to the level and timing of our new product development efforts.
Sales and marketing
Sales and marketing expenses primarily consist of personnel costs and benefits, third party logistics, fulfillment and outbound shipping costs, digital marketing, advertising, promotional, as well as conferences, meetings and other events and related facilities and information technology costs. We expect our sales and marketing expenses to increase in absolute dollars in the long term as we continue to increase the size of our direct sales force and sales support personnel and expand into new products and markets. We expect our sales and marketing expenses will also increase in the near term as we promote our brand through marketing and advertising initiatives, expand market presence and hire additional personnel to drive penetration and generate leads. We expect that sales and marketing expenses as a percentage of revenues will increase in the near term and then fluctuate over time as we evaluate expansion opportunities.
General and administrative
General and administrative expenses primarily consist of personnel costs and benefits, patent and filing fees, facilities costs, office expenses and outside services. Outside services consist of professional services, legal and other professional fees. We expect our general and administrative expenses to increase in absolute dollars in the foreseeable future. We anticipate general and administrative expenses as a percentage of revenues will increase in the near term and then fluctuate over time due to the timing and amount of these expenses. In addition, we expect to incur additional general and administrative expenses as a result of operating as a public company.
27
Other income (expense), net
Other income (expense), net primarily consists of foreign exchange gains or losses and investment gains or losses.
Provision for income taxes
Deferred tax assets are reduced by a valuation allowance to the extent management believes it is not more likely than not to be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income. Management makes estimates and judgments about future taxable income based on assumptions that are consistent with our plans and estimates. We recorded a full valuation allowance as of March 31, 2021 and December 31, 2020. We expect that income tax expense will be due to operations in profitable foreign subsidiaries.
Results of Operations
We operate as a single reportable segment to reflect the way our chief operating decision maker (“CODM”) reviews and assesses the performance of the business. The accounting policies are described in Note 2 in our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.
| | | | | | | | | | | | |
| | Three months ended March 31, |
| |||||||||
| | 2021 | | | 2020 |
| ||||||
| | | | | % of | | | | | | % of |
|
(in thousands) | | Dollars | | revenue | | | Dollars | | revenue |
| ||
Revenue: |
| |
|
|
|
| | |
|
|
| |
Product | | $ | 9,595 |
| 77.1 | % | | $ | 7,209 |
| 83.1 | % |
Subscription | | | 2,848 |
| 22.9 | % | | | 1,461 |
| 16.9 | % |
Total revenue: | | $ | 12,443 |
| 100.0 | % | | $ | 8,670 |
| 100.0 | % |
Cost of revenue: | | |
|
|
|
| | |
|
|
| |
Product | | | 5,648 |
| 45.4 | % | | | 9,262 |
| 106.8 | % |
Subscription | | | 379 |
| 3.0 | % | | | 244 |
| 2.8 | % |
Total cost of revenue: | | $ | 6,027 |
| 48.4 | % | | $ | 9,506 |
| 109.6 | % |
Gross profit | | $ | 6,416 |
| 51.6 | % | | $ | (836) |
| (9.6) | % |
| | | | | | | | | | | | |
Operating expenses: | | |
|
|
|
| | |
|
|
| |
Research and development | | | 15,716 |
| 126.3 | % | | | 12,516 |
| 144.4 | % |
Sales and marketing | | | 9,808 |
| 78.8 | % | | | 5,915 |
| 68.2 | % |
General and administrative | | | 34,640 |
| 278.4 | % | | | 5,242 |
| 60.5 | % |
Total operating expenses | | $ | 60,164 |
| 483.5 | % | | $ | 23,673 |
| 273.0 | % |
| | | | | | | | | | | | |
Loss from operations | | $ | (53,748) |
| (432.0) | % | | $ | (24,509) |
| (282.7) | % |
Interest income | | | 239 |
| 1.9 | % | | | 199 |
| 2.3 | % |
Interest expense | | | (638) |
| (5.1) | % | | | (5) |
| (0.1) | % |
Change in fair value of warrant liabilities | | | 54,112 | | 434.9 | % | | | — | | — | % |
Other income (expense), net | | | (631) |
| (5.1) | % | | | (29) |
| (0.3) | % |
| | | | | | | | | | | | |
Loss before provision for income taxes | | $ | (666) |
| (5.4) | % | | $ | (24,344) |
| (280.8) | % |
| | | | | | | | | | | | |
Provision for income taxes | | | 24 |
| 0.2 | % | | | 10 |
| 0.1 | % |
| | | | | | | | | | | | |
Net loss | | $ | (690) |
| (5.5) | % | | $ | (24,354) |
| (280.9) | % |
28
Comparison of the three months ended March 31, 2021 and 2020
Revenue
| | | | | | | | | | | | |
| | Three months ended March 31, | | | | | |
| ||||
(in thousands) | | 2021 | | 2020 | | Change | | % Change |
| |||
Revenue: |
| |
|
| |
|
| |
|
|
| |
Product |
| $ | 9,595 | | $ | 7,209 | | $ | 2,386 |
| 33.1 | % |
Subscription |
| | 2,848 | | | 1,461 | | | 1,387 |
| 94.9 | % |
Total revenue: | | $ | 12,443 | | $ | 8,670 | | $ | 3,773 |
| 43.5 | % |
Total revenue increased by $3.8 million, or 43.5%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020.
Product revenue increased by $2.4 million, or 33.1%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. The increase in product revenue was primarily driven by a higher volume of Butterfly iQ+ probes sold, as a result of our increased investment in our sales and marketing efforts.
Subscription revenue increased by $1.4 million, or 94.9%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. The increase was driven by an increased volume of our SaaS subscriptions sold in conjunction with sales of our devices as well as the increase from subscription renewals year over year.
Cost of revenue
| | | | | | | | | | | | |
| | Three months ended March 31, | | | | | |
| ||||
(in thousands) | | 2021 | | 2020 | | Change | | % Change |
| |||
Cost of revenue: |
| |
|
| |
|
| |
|
|
| |
Product |
| $ | 5,648 | | $ | 9,262 | | $ | (3,614) |
| (39.0) | % |
Subscription |
| | 379 | | | 244 | | | 135 |
| 55.3 | % |
Total cost of revenue | | $ | 6,027 | | $ | 9,506 | | $ | (3,479) |
| (36.6) | % |
Percentage of revenue | |
| 48.4 | % |
| 109.6 | % |
|
|
|
| |
Cost of product revenue decreased by $3.6 million, or 39.0%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. This decrease was driven by the sale of our second generation product, the Butterfly IQ+, in the quarter ended March 31, 2021 as opposed to the Butterfly IQ in the quarter ended March 31, 2020. The IQ+’s lower product cost and associated lower warranty cost primarily accounted for $2.9 million of the decrease in costs associated with product sales.
Cost of subscription revenue increased by $0.1 million, or 55.3%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. This increase was primarily driven by increased cloud hosting costs.
Research and development
| | | | | | | | | | | | |
| | Three months ended March 31, | | | | | |
| ||||
(in thousands) | | 2021 | | 2020 | | Change | | % Change |
| |||
Research and development |
| $ | 15,716 |
| $ | 12,516 |
| $ | 3,200 |
| 25.6 | % |
Percentage of revenue | |
| 126.3 | % |
| 144.4 | % |
|
|
|
| |
Research and development expenses increased by $3.2 million, or 25.6%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. This increase was primarily driven by increased personnel costs of $3.8 million as we continue to invest in expanding our internal research capabilities. These expenses were partially offset by a decrease in spending on fabrication services of $0.6 million.
29
Sales and marketing
| | | | | | | | | | | | |
| | Three months ended March 31, | | | | | |
| ||||
(in thousands) | | 2021 | | 2020 | | Change | | % Change |
| |||
Sales and marketing |
| $ | 9,808 |
| $ | 5,915 |
| $ | 3,893 |
| 65.8 | % |
Percentage of revenue | |
| 78.8 | % |
| 68.2 | % |
|
|
|
| |
Sales and marketing expenses increased by $3.9 million, or 65.8%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. This increase was primarily driven by increases in personnel cost and benefits of $2.7 million associated with increases in sales and sales personnel and an increase in demand generation costs of $0.9 million due to investments made to promote sales growth.
General and administrative
| | | | | | | | | | | | |
| | Three months ended March 31, | | | | | |
| ||||
(in thousands) | | 2021 | | 2020 | | Change | | % Change |
| |||
General and administrative |
| $ | 34,640 |
| $ | 5,242 |
| $ | 29,398 |
| 560.8 | % |
Percentage of revenue | |
| 278.4 | % |
| 60.5 | % |
|
|
|
| |
General and administrative expenses increased by $29.4 million, or 560.8%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. This increase is primarily due to an increase in stock-based compensation expense of $16.3 million due to the additional awards granted and the private placement of the Private Placement Warrants, our shares, debt or a combination of cash, equity and debt.
Loss from operations
| | | | | | | | | | | | |
| | Three months ended March 31, | | | | | |
| ||||
(in thousands) | | 2021 | | 2020 | | Change | | % Change |
| |||
Loss from operations |
| $ | (53,748) |
| $ | (24,509) |
| $ | (29,239) |
| 119.3 | % |
Percentage of revenue | |
| (432.0) | % |
| (282.7) | % |
|
|
|
| |
Loss from operations increased by $29.2 million, or 119.3%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. This increase was primarily a result of increases in operating expenses of $36.5 million partially offset by an initial Business Combination:increase in gross profit of $7.3 million. The increase in gross profit was primarily due to higher volume sales and lower cost of product revenue.
Interest expense
| | | | | | | | | | | | |
| | Three months ended March 31, | | | | | |
| ||||
(in thousands) | | 2021 | | 2020 | | Change | | % Change |
| |||
Interest expense |
| $ | (638) |
| $ | (5) |
| $ | (633) |
| 12,660.0 | % |
Percentage of revenue | |
| (5.1) | % |
| (0.1) | % |
|
|
|
| |
Interest expense increased by $0.6 million, or 12,660.0%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. This increase was driven by stated interest expense and amortization of debt issuance costs in connection with convertible notes that were issued after the first quarter of 2020.
30
Other income (expense), net
| | | | | | | | | | | | |
| | Three months ended March 31, | | | | | |
| ||||
(in thousands) | | 2021 | | 2020 | | Change | | % Change |
| |||
Other income (expense), net |
| $ | (631) |
| $ | (29) |
| $ | (602) |
| 2,075.9 | % |
Percentage of revenue | |
| (5.1) | % |
| (0.3) | % |
|
|
|
| |
Other expense increased by $0.6 million, or 2,075.9%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. This increase was driven primarily by an increase of investment losses of $0.5 million.
Net loss
| | | | | | | | | | | | |
| | Three months ended March 31, | | | | | |
| ||||
(in thousands) | | 2021 | | 2020 | | Change | | % Change |
| |||
Net loss |
| $ | (690) |
| $ | (24,354) |
| $ | 23,664 |
| (97.2) | % |
Percentage of revenue | |
| (5.5) | % |
| (280.9) | % |
|
|
|
| |
Net loss decreased by $23.7 million, or 97.2%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. This increase was primarily a result of a higher operating loss of $29.3 million offset by the gain for the change in the fair value of the warrant liabilities $54.1 million. The warrant liabilities were recorded as part of the business combination and therefore did not exist in the prior year.
Liquidity and Capital Resources
Since our inception, our primary sources of liquidity are cash flows from operations and issuances of preferred stock and convertible notes. In addition, on February 12, 2021, we issue debt securities or otherwise incur significant debt, it couldcompleted the Business Combination, and as a result in:
We expect to continue to incur significant costsnet losses in the pursuitshort term, as we continue to invest in research and development of our acquisition plans. products and invest in the sales and marketing and expand into new markets and verticals.
We cannot assure youexpect that our plans to complete our initialthe funds raised in connection with the Business Combination and cash flows from operations will be successful.sufficient to meet our liquidity, capital expenditure, and anticipated working capital requirements and fund our operations for at least the next 12 months. We expect to use the funds raised in connection with the Business Combination to scale our sales and marketing capabilities, develop new products and services, and for working capital and general corporate purposes.
Our cash and cash equivalents and investment in marketable securities balance as of March 31, 2021 was $545.3 million. Our future capital requirements may vary from those currently planned and will depend on various factors, including our rate of revenue growth and the timing and extent of spending on strategic business initiatives.
31
Cash flows
Comparison of Operations
The following table summarizes our sources and uses of cash for the Initial Public Offering, identifyingthree months ended March 31, 2021 and March 31, 2020:
| | | | | | |
| | Three months ended March 31, | ||||
(in thousands) | | 2021 | | 2020 | ||
Net cash used in operating activities |
| $ | (63,427) |
| $ | (19,670) |
Net cash used in investing activities |
| | (528,197) |
| | (480) |
Net cash provided by financing activities |
| | 550,268 |
| | 154 |
Net decrease in cash and cash equivalents |
| $ | (41,356) |
| $ | (19,996) |
Cash flows used in operating activities
Net cash flows used in operating activities represent the cash receipts and disbursements related to our activities other than investing and financing activities. We expect cash provided by financing activities will continue to be our primary source of funds to support operating needs and capital expenditures for the foreseeable future.
Net cash used in operating activities increased by $43.8 million, or 222.5%, to $63.4 million for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. The increase in net cash used in operating activities for the three months ended March 31, 2021 compared with the three months ended March 31, 2020 was due to a target company for$10.9 million increase in inventory levels resulting from increased inventory purchases and a Business Combination. We do not expect$4.6 million increase in prepaid expenses and other assets to generate any operating revenues until after the completion of our Business Combination. We generate non-operating incomebe used in the form of interest income earned on marketable securities held in the trust account (“Trust Account”). We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance),operations, as well as a $14.9 million decrease in accounts payable and accrued expenses due to the timing of expenses and payments, a $35.8 million decrease in adjustments to reconcile net loss partially offset by $23.7 million decrease in net losses.
Cash flows used in investing activities
Net cash used in investing activities increased by $527.7 million from $0.5 million to $528.2 million for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. The increase was primarily due diligence expenses in connection with completing ato the investment activity for the funds received from the Business Combination.
Cash flows provided by financing activities
For the three months ended September 30, 2020, we had aMarch 31, 2021, net losscash provided by financing activities was $550.3 million compared with $0.2 million for the three months ended March 31, 2020. This increase of $327,036, which consists$550.1 million was primarily due to net proceeds from the Business Combination of operating costs$547.8 million and proceeds from the exercise of $462,905 and provision for income taxesstock options of $29,152,$6.3 million partially offset by interest income on marketable securities held inour $4.4 million loan repayment under the Trust AccountPaycheck Protection Program.
Contractual Obligations
As of $165,021.March 31, 2021, our contractual obligations were as follows:
| | | | | | | | | | | | | | | |
(in thousands) |
| Total |
| < 1 year |
| 1-3 Years |
| 3-5 Years |
| > 5 years | |||||
Operating leases |
| $ | 16,095 |
| $ | 1,360 |
| $ | 3,936 |
| $ | 3,945 |
| $ | 6,854 |
Purchase obligations (1) |
| | 156,061 |
| | 53,040 |
| | 103,021 |
| | — |
| | — |
Total contractual obligations |
| $ | 172,156 |
| $ | 54,400 |
| $ | 106,957 |
| $ | 3,945 |
| $ | 6,854 |
(1) | Purchase obligations include all legally binding contracts and relate to firm commitments for inventory purchases. Our purchase obligations are related to a contract for a key inventory component in our manufacturing process. Purchase orders that are not binding agreements are excluded from the table above. |
32
Critical Accounting Policies and provision for income taxes of $29,152, offset by interest income on marketable securities held in the Trust Account of $222,151.
Our management's discussion and loans from our Sponsor.
Except as described in Note 2, “Summary of Significant Accounting Policies – Recent Accounting Pronouncements Adopted” and “Summary of Significant Accounting Policies – Recent Accounting Pronouncement Issued but Not Yet Adopted,” to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, there have identified the followingbeen no material changes to our critical accounting policies:
Recently Adopted Accounting Pronouncements
A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 in our condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q.
Emerging Growth Company
We accountare an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Pursuant to the JOBS Act, an emerging growth company is provided the option to adopt new or revised accounting standards that may be issued by FASB or the SEC either (i) within the same periods as those otherwise applicable to non-emerging growth companies or (ii) within the same time periods as private companies. We intend to take advantage of the exemption for our common stock subjectcomplying with new or revised accounting standards within the same time periods as private companies. Accordingly, the information contained in this report may be different than the information you receive from other public companies.
We also intend to possible redemption in accordancetake advantage of some of the reduced regulatory and reporting requirements of emerging growth companies pursuant to the JOBS Act so long as we qualify as an emerging growth company, including, but not limited to, not being required to comply with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the controlauditor attestation requirements of Section 404(b) of the holder or subject to redemption uponSarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation, and exemptions from the occurrencerequirements of uncertain eventsholding non-binding advisory votes on executive compensation and golden parachute payments.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Interest Rate Risk
We did not solely within our control) is classifiedhave any floating rate debt as temporary equity. At all other times, common stock is classified as stockholders’ equity.of March 31, 2021. Our common stock features certain redemption rights thatcash, cash equivalents and marketable securities are considered to be outsidecomprised primarily of bank deposits and equity interests in mutual funds. The primary objective of our control and subjectinvestments is the preservation of capital to occurrence of uncertain future events. Accordingly, the common stock subject to possible redemption is presented as temporary equity, outside of the stockholders’ equity section of our condensed balance sheet.
Foreign Exchange Risk
We operate our business primarily within the United States and currently execute the majority of our transactions in U.S. dollars. We have not utilized hedging strategies with respect to such foreign exchange exposure. This limited foreign currency translation risk is not expected to have a material exposure to interest rate risk.impact on our condensed consolidated financial statements.
33
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’sSecurities and Exchange Commission’s rules and forms. Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed in our company’s reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.
Material Weakness in Rules 13a-15(e)Internal Control over Financial Reporting
As previously disclosed in our Amendment No. 1 to our Annual Report on Form 10-K/A for the year ended December 31, 2020, we identified a material weakness in our internal controls over financial reporting related to inaccurate accounting for public warrants and 15d-15(e) underprivate placement warrants issued in connection with our initial public offering. Notwithstanding this material weakness, management has concluded that our unaudited financial statements included in this Quarterly Report on Form 10-Q are fairly stated in all material respects in accordance with GAAP for each of the Exchange Act) were effective.periods presented therein.
Our internal control over financial reporting did not detect the proper accounting and reporting for our public warrants and private placement warrants issued in connection with the Company’s initial public offering in May 2020. Management identified this error when the SEC issued a Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”) dated April 12, 2021 (the “SEC Staff Statement”). The SEC Staff Statement addresses certain accounting and reporting considerations related to warrants of a kind similar to those we issued in connection with our initial public offering in May 2020. This control deficiency resulted in the Company having to restate its audited consolidated financial statements contained in its Annual Report on Form 10-K for the year ended December 31, 2020 and if not remediated, could result in a material misstatement to future annual or interim consolidated financial statements that would not be prevented or detected. Accordingly, management has determined that this control deficiency constitutes a material weakness.
Plan for Remediation of the Material Weakness in Internal Control over Financial Reporting
In response to this material weakness, the Company’s management has expended, and will continue to expend, a substantial amount of effort and resources for the remediation and improvement of our internal control over financial reporting. While we have processes to properly identify and evaluate the appropriate accounting technical pronouncements and other literature for all significant or unusual transactions, we are improving these processes to ensure that the nuances of such transactions are effectively evaluated in the context of the increasingly complex accounting standards. Our plans at this time include acquiring enhanced access to accounting literature, research materials and documents and increased communication among our personnel and third-party professionals with whom we may consult regarding the application of complex accounting transactions. Our remediation plan can only be accomplished over time and will be continually reviewed to determine that it is achieving its objectives. This is no assurance that these initiatives will ultimately have the intended effects.
34
Changes in Internal Control Overover Financial Reporting
Other than the most recently completed fiscal quarter,changes made to remediate the material weakness described above, there has beenwere no changechanges in our internal control over financial reporting (as definedidentified in connection with the evaluation required by Rules 13a-15(f)13a-15(d) and 15d-15(f) under15d-15(d) of the Exchange Act)Act that hasoccurred during the three months ended March 31, 2021 that have materially affected, or isare reasonably likely to materially affect, our internal control over financial reporting.
Limitations on the Effectiveness of Disclosure Controls and Procedures
Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and implemented, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues within a company are detected. The inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple errors or mistakes. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.
PART II -— OTHER INFORMATION
Item 1. Legal Proceedings
On December 14, 2020, Nidhish Nair, a purported stockholder of Longview, filed a lawsuit in the Supreme Court of the State of New York, County of New York, captioned Nair v. Longview Acquisition Corp., against Longview and the members of its board directors, or the Nair Complaint. On December 16, 2020, Eric Lau, a purported stockholder of Longview, filed a lawsuit in the Supreme Court of the State of New York, County of New York, captioned Lau v. Longview Acquisition Corp., against Longview, the members of its board of directors, and Legacy Butterfly, or the Lau Complaint. The Nair Complaint and the Lau Complaint, which we refer to collectively as the Complaints, asserted a breach of fiduciary duty claim against the individual defendants and an aiding and abetting claim against Longview in connection with the Business Combination between Longview and Legacy Butterfly. The Lau Complaint also asserted an aiding and abetting claim against Legacy Butterfly. The Complaints alleged, among other things, that could cause our actual results(i) defendants engaged in an unfair sales process and agreed to differ materially from thoseinadequate consideration in this report includeconnection with the risk factors described in our final prospectusBusiness Combination, and (ii) that the Registration Statement on Form S-4 filed with the SEC on November 27, 2020 in connection with the Business Combination was materially misleading. The Complaints sought, among other things, to enjoin the Business Combination, rescind the transaction or award rescissory damages to the extent it is consummated, and an award of attorneys’ fees and expenses. The Nair Complaint was voluntarily dismissed on February 21, 2021, and the Lau Complaint was voluntarily dismissed on March 2, 2021. The parties currently are in negotiation regarding a potential attorney fee award.
Item 1A. Risk Factors
Our business, results of operations and financial condition are subject to various risks and uncertainties including the risk factors found under the caption “Risk Factors” in our most recent Annual Report on Form 10-K, filed with the SEC on March 29, 2021 , as amended on May 22, 2020. As of the date of this12, 2021 (the “2020 Annual Report other than as described below, thereon Form 10-K). There have been no material changes to the risk factors disclosed in our final prospectus filed with the SEC.
Item 2. Unregistered Sales of interest, which could reduceEquity Securities and Use of Proceeds
Unregistered Sales of Equity Securities
Not applicable.
35
Issuer Purchases of Equity Securities
We did not repurchase any of our equity securities during the value ofquarter ended March 31, 2021.
Item 3. Defaults Upon Senior Securities
Not applicable.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
On May 3, 2021, the assets held in trust such that the per-share redemption amount received by public stockholders may be less than $10.00 per share.
Under the Severance Plan, if we terminate a participant’s employment without cause (as defined in the United States. InSeverance Plan) or a participant resigns for good reason (as defined in the event that we are unable to complete our initial business combination or make certain amendments to our Amended and Restated Certificate of Incorporation, our public stockholders are entitledSeverance Plan) at any time other than during the twelve (12) month period following a change in control (as such term is defined in the Severance Plan) (the “Change in Control Period”), then the participant is eligible to receive their pro-rata sharethe following benefits:
| ● | Severance payable in the form of salary continuation. The severance amount is equal to participant’s then-current base salary times a multiplier determined based on the participant’s title or role with the Company. |
| ● | We will pay for company contribution for continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, or COBRA, during the severance period. |
Under the Severance Plan, if we terminate a participant’s employment without cause or participant resigns for good reason, during the Change in Control Period, then the participant is eligible to receive the following benefits:
| ● | Severance payable in a single lump sum. The severance amount is equal to participant’s then-current base salary and then-current target annual bonus opportunity, times a change in control multiplier determined based on the participant’s title or role with the Company. |
| ● | We will pay for company contribution for continuation coverage under COBRA during the severance period. |
| ● | Any outstanding unvested equity awards held by the participant under our then-current outstanding equity incentive plan(s) will become fully vested on the date the termination of such participant’s employment becomes effective. |
A participant’s rights to any severance benefits under the Severance Plan are conditioned upon the participant executing and not revoking a valid separation and general release of the proceeds heldclaims agreement in the Trust Account, plus any interest income not released to us, neta form provided by us.
Item 6. Exhibits
See Exhibit Index.
36
EXHIBIT INDEX
| | | | | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Exhibit Number | | Exhibit Description | | Filed Herewith | | Incorporated by Reference herein from Form or Schedule | | Filing Date | | SEC File/ Reg. Number |
2.1† | | | | | Form 8-K (Exhibit 2.1) | | 11/23/2020 | | 001-39292 | |
3.1 | | Second Amended and Restated Certificate of Incorporation of Butterfly Network, Inc. | | | | Form 8-K (Exhibit 3.1) | | 2/16/2021 | | 001-39292 |
3.2 | | | | | Form 8-K (Exhibit 3.2) | | 2/16/2021 | | 001-39292 | |
4.1 | | | | | Form 8-K (Exhibit 4.1) | | 2/16/2021 | | 001-39292 | |
10.5.1@ | | | | | Form S-4 (Exhibit 10.13.1) | | 11/27/2020 | | 333-250995 | |
10.5.2@ | | | | | Form S-4 (Exhibit 10.13.2) | | 11/27/2020 | | 333-250995 |
37
| | | | | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Exhibit Number | | Exhibit Description | | Filed Herewith | | Incorporated by Reference herein from Form or Schedule | | Filing Date | | SEC File/ Reg. Number |
10.6.1@ | | | | | Form S-4 (Exhibit 10.14.1) | | 11/27/2020 | | 333-250995 | |
10.6.2@ | | | | | Form S-4 (Exhibit 10.14.2) | | 11/27/2020 | | 333-250995 | |
10.6.3@ | | | | | Form 10-K/A (Exhibit [10.6.3]) | | 5/[●]/2021 | | 001-39292 | |
10.7@ | | | | | Form S-4 (Exhibit 10.15) | | 11/27/2020 | | 333-250995 |
38
| | | | | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Exhibit Number | | Exhibit Description | | Filed Herewith | | Incorporated by Reference herein from Form or Schedule | | Filing Date | | SEC File/ Reg. Number |
10.8.1@ | | | | | Form S-4/A (Exhibit 10.17.1) | | 1/6/2021 | | 333-250995 | |
10.8.2@ | | | | | Form S-4/A (Exhibit 10.17.2) | | 1/6/2021 | | 333-250995 | |
10.9 | | | | | Form S-4/A (Exhibit 10.18) | | 1/6/2021 | | 333-250995 | |
10.10+ | | Form S-4/A (Exhibit 10.14) | 1/26/2021 | | 333-250995 |
39
| | | | | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Exhibit Number | | Exhibit Description | | Filed Herewith | | Incorporated by Reference herein from Form or Schedule | | Filing Date | | SEC File/ Reg. Number |
10.11+ | | Form S-4 (Exhibit 10.9) | 11/27/2020 | | 333-250995 | |||||
10.12+ | | Form S-4/A (Exhibit 10.11) | 1/6/2021 | | 333-250995 | |||||
10.13+ | | Form S-4/A (Exhibit 10.12) | 1/6/2021 | | 333-250995 | |||||
10.14+ | | Form S-4/A (Exhibit 10.10) | 1/6/2021 | | 333-250995 |
40
| | | | | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Exhibit Number | | Exhibit Description | | Filed Herewith | | Incorporated by Reference herein from Form or Schedule | | Filing Date | | SEC File/ Reg. Number |
10.15+ | | Form S-4/A (Exhibit 10.13) | 1/6/2021 | | 333-250995 | |||||
10.16+ | | Form S-4 (Exhibit 10.8) | 11/27/2020 | | 333-250995 | |||||
10.17+ | | Form S-4/A (Exhibit 10.8.2) | 1/26/2021 | | 333-250995 | |||||
10.18+ | | Form 10-K (Exhibit 10.18) | 3/29/21 | | 001-39292 | |||||
10.19.1+ | Butterfly Network, Inc. Amended and Restated 2020 Equity Incentive Plan. | | Form 10-K (Exhibit 10.19.1) | 3/29/21 | | 001-39292 | ||||
10.19.2+ | Form of Stock Option Agreement under 2020 Equity Incentive Plan. | | Form 8-K (Exhibit 10.15.2) | 2/16/21 | | 001-39292 | ||||
10.19.3+ | Form of Restricted Stock Unit Agreement under 2020 Equity Incentive Plan. | | Form S-8 (Exhibit 99.3) | 5/12/21 | | 333-256044 |
41
| | | | | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Exhibit Number | | Exhibit Description | | Filed Herewith | | Incorporated by Reference herein from Form or Schedule | | Filing Date | | SEC File/ Reg. Number |
10.20.1+ | BFLY Operations, Inc. 2012 Employee, Director and Consultant Equity Incentive Plan, as amended. | | Form 10-K (Exhibit 10.20.1) | 3/29/21 | | 001-39292 | ||||
10.20.2+ | | Form 8-K (Exhibit 10.16.2) | 2/16/21 | | 001-39292 | |||||
10.20.3+ | | Form 8-K (Exhibit 10.16.3) | 2/16/21 | | 001-39292 | |||||
10.21+ | | Form 8-K (Exhibit 10.17) | 2/16/21 | | 001-39292 | |||||
10.22+ | | | | | Form S-1/A | | 5/12/21 | | 333-254836 | |
10.23+ | | Form 8-K (Exhibit 10.18) | 2/16/21 | | 001-39292 | |||||
10.24 | | Form 8-K (Exhibit 10.19) | 2/16/21 | | 001-39292 | |||||
10.25 | | Form 8-K (Exhibit 10.20) | 2/16/21 | | 001-39292 |
42